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ABSTRACT

Alzheimer's disease (AD) is characterized histopathologically by neurofibrillary
tangles, senile plaques, reactive astrocytes and microglia, neuronal shrinkage, and cell loss
in various brain regions. These pathological changes are associated with neurochemical
deficits and cognitive impairments. Senile plaques consist predominantly of amyloid-P (APl
peptide, that has been proposed to have a prominent role in the pathogenesis of AD. The
main component of the tangles is paired helical filaments, which consist largely of the
protein tau in an abnormal state of phosphorylation. There is currently no treatment
available that effectively slows or halts the progression of AD. The main reason for this is
the relative lack of an animal model that has the features of the disease, in which potential
therapeutic drugs could be screened. The main objective of this dissertation work was to
develop a rat model of the histopathological hallmarks of AD.
Because the early and primary histopathological changes in AD are predominantly
found in temporal lobe structures, it was determined if intra-amygdaloid injections of AP 25-

35 in the rat induced the appearance of abnormal tau proteins and reactive astrocytes as
seen in AD. It was also examined if the effects of AP were time dependent, included
neuronal shrinkage and microglial activation, and if these changes were associated with
neurochemical and behavioral alterations.
AP induced abnormal neuronal tau staining in the right amygdala and hippocampus.
AP also induced reactive astrocytosis and neuronal shrinkage within the right hippocampus
and amygdala, respectively. The same brain regions within the left hemisphere were
significantly less affected. In addition, AP appeared to induce microglial proliferation and

xi

neuronal interleukin-1 P staining. The histopathological effects of

AP

peaked at 32 days

postoperatively and were associated with minimal behavioral impairments. These effects
were not associated with a reduction in amygdaloid choline acetyltransferase activity at 32
days postinjection.
These data demonstrate that intra-amygdaloid injections of

AP

induce transsynaptic

cytoskeletal and astrogliotic reactions. These findings also suggest a laterality in the
histopathological effects of

AP

and that the effects of single injections are in part transient.

Identification of the cause for the lateralized effect of

AP

may prove valuable for

understanding the etiology of AD and provide possible therapeutic strategies designed to
slow the progression of the disease. In addition, these results suggest a direct association
between plaque and tangle formation in AD, and support the use of this rat model to screen
drugs that may alter the initial pathological events associated with AD.

xii

CHAPTER I
INTRODUCTION

Alzheimer's disease (AD) was originally characterized by Alo is Alzheimer in 1 907.
The histopathological characteristics of AD include neurofibrillary tangles, senile plaques,
reactive astrocytes and microglia, neuronal shrinkage, and cell loss in several brain regions.
These pathological changes are associated with neurochemical deficits and cognitive
impairments. The main component of the neurofibrillary tangles is paired helical filaments
( 168,335), that consist largely of the microtubule associated protein tau in an abnormal
state of phosphorylation (171, 183,355,356). Reactive astrocytes and microglia have larger
cytoplasm and thicker and more branched processes than they do when in their resting
states. Senile plaques in the AD brain are associated with reactive astrocytes
(70, 126, 128,250) and microglia (122, 155,228). Senile plaques consist predominantly of
amyloid-J3 ( AJ3) 1-42 peptide (103,214,233,285), which is derived from a large membrane
spanning protein, the amyloid-J3 precursor protein (APP) ( 1 66). Mutations in APP in some
forms of familial AD are associated with an elevated production of AJ3 (33,39,331 ). APP is
overexpressed in Down's syndrome (248,291), and individuals with this disease invariably
develop the neuropathological hallmarks of AD (23, 187). The proposed role for AJ3 in the
pathogenesis of AD is further supported by the neurotoxicity of AJ3 (369,370), which
includes amino acids 25-35 of the peptide (370). Currently, AD is the fourth leading cause
of death in the developed world. Advanced age is the major risk factor for AD, and the
prevalence of AD is expected to rise substantially in the near future because of the aging
population. Numerous advances have been made in recent years in elucidating the
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mechanism of neuronal degeneration in AD. Several risk factors for AD are now known but
the sequence of pathogenic events that eventually lead to dementia remains a mystery.
There is currently no treatment available that effectively slows or halts the progression of
the disease. The main reason for this is a lack of an adequate animal model that has all the
features of the disease, in which potential therapeutic drugs could be screened. The main
objective of this dissertation work was to develop a rat model of the histopathological
hallmarks of AD.
Because the early and primary histopathological changes in AD are predominantly
found in temporal lobe structures, we assessed the hypotheses that

A~

25-35 injections into

the amygdala of the rat would induce the appearance of abnormal microtubule associated
protein tau and reactive astrocytes as seen in AD. We also tested the hypotheses that the
effects of

A~

25-35 would be time dependent and include neuronal shrinkage and microglial

activation. Furthermore, we examined the hypotheses that these histological changes would
be associated with neurochemical and behavioral alterations.

3
REVIEW OF THE RELEVANT LITERATURE

Amyloid-13 Precursor Protein

Three major isoforms of APP are produced by alternative splicing. lsoforms of 751
and 770 amino acids are expressed in both neural and non-neural tissue (169,275,333),
whereas a 695 amino acid isoform is mostly expressed in neurons (172,365). APP is
processed through at least two proteolytic pathways. The major pathway is a secretory
pathway which leads to cleavage of APP within the extracellular portion of the AP peptide
(between residues 16 and 17) (78), that generates a 90-100 kDa secreted form (APPs)
(78,318,349). This cleavage is performed by an unknown enzyme named a-secretase. This
pathway is considered non-amyloidogenic because intact AP is not formed. APP also is
processed through an amyloidogenic endosomal/lysosomal pathway (44,80, 107, 119). This
alternative pathway generates intact AP that is processed from APP by unknown enzymes
termed P- and y-secretase. It was believed that intact AP was not generated during normal
APP processing (31 8), but it has recently been demonstrated that AP is produced and
secreted during normal metabolism (24, 120,307,313). Analysis of APP metabolism in
primary cell cultures of neurons, astrocytes and microglia indicates that neurons generate
more AP than astrocytes or microglia ( 1 90).
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APP

f3 a

y

'' '
I

I

Af3 1 - 42

Figure 1. APP processing enzymes. Schematic presentation of the enzymatic cleavage of
APP. A cleavage of APP by ~- and y-secretases is considered amyloidogenic because it
leads to the production of A~ 1-42, the most prominent form of A~ in senile plaques.
Alternatively, a cleavage by a-secretase is considered non-amyloidogenic because intact A~
is not formed. The arrows labeled a, ~. and y represent the respective secretases.
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The role of APP, APPs and

A~

in the brain is not well understood. APP associates

with G proteins (251 ), suggesting that it may serve as a receptor. Overexpression of APP
has synaptotrophic effects in the cortex of transgenic mice and protects against the
neurotoxicity of the gp 120 protein found in the human immunodeficiency virus (240,241 ).
APP is not essential during development because homozygous APP-knockout mice proceed
through gestation normally (371 ). As adults, they are fertile but exhibit a 15-20% decrease
in body weight, decreased locomotor activity, and a loss of forelimb grip strength. Diffuse
reactive gliosis is observed in the brains of these animals without clear neuronal
degeneration.
Cerebrospinal fluid levels of APPs are decreased in AD (339). APPs stimulates cell
growth (295), promotes cell adhesion (20,38, 167,234,303), and mediates the effects of
nerve growth factor on neurite outgrowth (234). At the molecular level, APPs activates
potassium channels (96) and increases the activity of microtubule associated protein kinase
( 11 6). APPs protects cultured neurons from the damaging effects of glucose deprivation,
excitatory amino acids, and oxidation, possibly through stabilization of intracellular calcium
(217 ,302). It is possible that a reduction in the production of APPs is associated with an
increase in

A~

toxic insults.

production, both of which would result in increased neuronal vulnerability to

6
AB Peptide

The proposed direct role for Al3 in the pathogenesis of AD is supported by the
association of AD with inherited APP mutations; APP overexpression in Down's syndrome;
and, the neurotoxicity of Al3 fibrils.

H2 N-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-AlaGlu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-lle-lle-Gly-Leu-Met-Val-Gly-Gly-Val-Val-lle-Ala-OH

Figure 2. Amino acid sequence of Al3 1-42 and Aj3 25-35 (underlined).

Normal processing of APP results in more production of Al3 1-40 than Aj3 1-42
(331,336). The preferential deposition of Al3 1-42 in senile plaques (285) is likely due to its
lesser solubility than Al3 1-40, and that it is more prone to aggregate and form 13-pleated
sheets (11,22,81, 124, 161, 162). The first APP mutation found in AD kindreds was
identified at codon 71 7 ( 104). Expression of this mutant APP in cultured cells results in
increased production of Al3 1-42 (331). Another inherited double APP mutation at codons
670 and 671 (242) results in an increase in Al3 production in transfected cells (33,39). APP
is overexpressed in Down's syndrome (248,291) and individuals with this disease invariably
develop the neuropathological hallmarks of AD (23, 1 87).

In vitro studies indicate that Al3 1-28 has a neurotrophic effect on cultured
hippocampal neurons (353), and that Al3 25-35 is a neurotrophic factor at low
concentrations (nM) in differentiating neurons but is neurotoxic at high concentrations (µM)
in mature neurons (370). Al3 toxicity in cell culture (273,284,368-370) depends on its
aggregation state (25,220,269,273), and requires the assembly of Aj3 into amyloid fibrils
composed of a 13-pleated sheet structure (26, 144,203). These in vitro findings correlate
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well with the observation that histopathological changes in AD are associated with senile
plaques that are composed of
amorphous

A~

A~

fibrils, but not with diffuse plaques composed of

aggregates (210,366). Various compounds bind to

A~

and enhance its

fibrillation in vitro, including apolipoprotein E (ApoE) (205,296,326,359), heparan sulfate
proteoglycan (90), and aluminum, iron and zinc ions (29,83,213). In addition, metalcatalyzed oxidation of AP results in the formation of highly insoluble aggregates (71).

A~

in

vitro develops resistance to protease degradation when polymerized into fibrils (252). Other
amyloidogenic peptides also are toxic to neurons in vitro, including amylin, serum amyloid P
component, and a peptide derived from the prion protein (87,202,222,338). These findings
suggest that the tertiary structure of the fibril, rather than its amino acid sequence, is
responsible for its toxicity.
A~

1-42 has been shown to bind to the serpin-enzyme complex (SEC) receptor on

cultured hepatoma cells (165). AP 25-35, 31-35, 1-39, and
A~

A~

1-40 have similar affinity as

1-42 for the receptor ( 1 9). The SEC receptor is present on PC 12 cells as well as in

primary culture of murine cortical neurons, and the selectivity of neuronal SEC receptor for
A~

is identical to that of hepatoma cells (19). The SEC receptor has been demonstrated to

mediate internalization and degradation of AP in PC12 cells (19). In addition, this receptor
recognizes the soluble non-toxic AP but not the aggregated cytotoxic AP, suggesting that
the receptor may have a protective role by mediating clearance and metabolism of soluble
A~

( 1 8). Furthermore, AP binds to the receptor for advanced glycation end products

(RAGE) in neurons, microglia and vascular endothelial cells (367). This interaction mediates
cell adhesion to AP and induces production of reactive oxygen species in microglia. The
class A scavenger receptor has also been demonstrated to mediate adhesion of microglia to
A~

that causes secretion of reactive oxygen species and cell immobilization (76). In

addition,

A~

has been observed to form an ion channel in artificial lipid membranes (6).
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A~

in vitro has been observed to potentiate the neurotoxicity of excitatory amino

acids (170,218), glucose deprivation (48), and oxidative stress (196). Conversely, other
studies have reported that glutamate antagonists do not prevent

A~

toxicity (28,269).

A~

also impairs mitochondrial redox activity and increases the generation of free radicals
(14,308). Some reports have suggested that antioxidants inhibit the toxicity of A~ and
other amyloidogenic peptides (14), whereas other studies find no protective effect of the
same antioxidants (196,202). The neurotoxicity of

A~

and other amyloidogenic peptides has

been shown to be mediated by an increase in intracellular calcium (218,219), but calcium
channel blockers and calcium chelating agents do not inhibit

A~

neurotoxicity (202,352).

These discrepancies, which may be due to differences in culture conditions, clearly
demonstrate the limitations of in vitro culture systems and show that caution must be taken
in extrapolating in vitro findings to in vivo situations.
The two basic pathways or mechanisms of cell death are necrosis and apoptosis. In

vitro studies have observed that

A~

induces both apoptosis (88,200,347) and necrosis (13).

Another amyloidogenic peptide, amylin, has been shown to induce apoptosis in pancreatic
islet cells (202). Some neurons in AD brain appear to undergo apoptosis (2, 189,328), and
cortical neurons from Down's syndrome brains generate increased levels of reactive oxygen
species that leads to apoptotic cell death in culture (27).
The reproducibility of

A~

toxicity in vivo has been inconsistent

(42,91,99, 101, 102, 178, 180,314,320,354). This may be due to variations in: 1) the
conformational state (25,269,273), dose, and sequence of A~; 2) method of administration;
3) pathological endpoints measured; 4) what brain region and/or hemisphere is injected; 5)
postoperative interval; and, 6) species and/or strain used. The consistency and persistence
of A~ deposits within the brain may also depend on similar factors. A~ in vitro develops
protease resistance to degradation when polymerized into fibrils (252). The presence of
heparan sulfate proteoglycans has been shown to be important for consistent in vivo
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deposition of AP 1-40 and persistence of fibrillar AP in the rat hippocampus (321 ). Also, AP
25-35 deposits within the rat nucleus basalis are degraded more rapidly than AP 1-40
deposits ( 102). Furthermore, acetylcholinesterase (AChE) has been shown to promote the
formation of and/or stabilization of AP fibrils ( 1 50).
It can be argued that because AP 1-42 is the most prevalent form of AP in senile
plaques, it is appropriate to use that peptide for injections into brain instead of AP 25-35.
However, the main problem with using AP 1-42 is its insolubility in physiological solvents.
Therefore, there is a risk of potentially toxic solvents interfering with the properties and
effects of AP 1-42. On the other hand, AP 25-35 is readily soluble in H 2 0 and acquires the
same p-pleated sheet conformation as AP 1-42, which is the toxic conformation of AP.
Only recently have a few studies demonstrated a direct association between plaque
and tangle formation in AD. In vitro studies have demonstrated that AP increases tau
protein kinase I (TPK I) activity (332), induces abnormal tau immunoreactivity (IR) (26,207),
and that the neuronal death caused by AP can be prevented with TPK I antisense
oligonucleotides (332). These findings suggest an association between plaque and tangle
formation in AD. A few in vivo studies have investigated the effects of AP injected into the
central nervous system (CNS) on tau IR (42,91,99, 178, 180,274). Some of these studies
indicate that AP can induce the appearance of abnormal tau proteins in the vicinity of the
injection site (rat cerebral cortex and hippocampus) (91, 178, 180). Other studies have failed
to show any effect (42,99,274). For the most part, these in vivo studies have only been
qualitative or descriptive in nature. No attempts have been made to quantify AP induced
effects by counting neuronal tau IR cells.
The effects of AP on tau IR may be mediated through an increase in intracellular
calcium. AP has been shown to increase intracellular calcium (7,218), and calcium influx in
cultured rat hippocampal neurons caused by glutamate induces tau IR as recognized by the
antibodies Alz-50 and 5E2 (21 6). Protein kinases are generally activated by increases in
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intracellular calcium and several of those have been shown to phosphorylate different sites
on tau proteins (238). Therefore, AP may increase the phosphorylation of tau proteins
through an activation of kinases mediated by an increase in intracellular calcium. The
activities of some phosphatases that may dephosphorylate tau proteins have been shown to
be decreased in AD (111,311 ). Therefore, AP 25-35 may also be decreasing the
dephosphorylation of tau proteins through an inhibition of phosphatases.

Effects of Al3 Peptide on Behavior

Only a few studies have investigated the effects of AP injections on behavior and
the experimental procedures vary substantially. It is, therefore, appropriate to give a
somewhat detailed description of these findings. Because of the nature of behavioral
experiments, it is necessary to support alterations in behavior with neurochemical and/or
histological findings.
Flood et al. (85) observed that intracerebroventricular (i.c.v.) administration in mice
of [Gin 11 lAP 1-28, AP 12-28, AP 18-28 and AP 12-20 immediately after training in a
footshock active avoidance test caused dose dependent retention deficits in the same test
one week later. This effect may be specific to memory processing because the peptides did
not cause amnesia when injected 24 h after training nor did they disturb storage or retrieval
of older memories. lntrahippocampal injection of [Gln11 lAP 1-28 produced amnesia at
much lower doses ( < 1 nmol) than an i.c.v. injection (approximately 1.5 - 6 nmol).
Maurice et al. (221) showed that AP 25-35 injected i.c.v. in mice induced dose
dependent decreases in both alternation behavior in the Y-maze 6 days postinjection and
passive avoidance test 7-8 days postoperatively, at doses of 3 and 9 nmol/mouse. Both the
cholinesterase inhibitor tacrine and the nicotinic receptor agonist (-)-nicotine induced a dose
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dependent abrogation of the
tacrine also reversed

A~

A~

25-35 induced behavioral impairments. Furthermore,

25-35 induced impairment of place learning and retention in a

water maze. A moderate bilateral cell loss and Congo red positive amyloid deposits were
observed at 21 days postoperatively within the frontoparietal cortex and in the CA3 region
of the hippocampal formation in animals that received 9 nmol
indic~te

that the deposition of

A~

A~

25-35. These results

in the brain is in some way related to impairment of

learning and cholinergic degeneration, and furthermore suggest that the 25-35 fragment of
A~

that is sufficient to induce neuronal death in cultures also induces an AD type amnesia in

mice.
One of the first studies to demonstrate a behavioral effect of
performed by Tate et al. (334), and did not use injections of
transfected cells that overexpress

A~.

A~

A~

in rats was

but rather a grafting of

These cells were grafted into the suprachiasmatic

nuclei of adult rats and led to disruption of circadian activity. AD patients exhibit
irregularities in the patterns of circadian rhythms and this finding suggests that

A~

may have

a role in these changes. However, it should be noted that the control groups did not include
animals grafted with non-transfected cells.
Nabeshima et al. (244) demonstrated that continuous infusions of

A~

1-40 (3, 30

and 300 pmol/day) for two weeks into the cerebral ventricles in adult rats led to impaired
performance in water maze (9-1 3 days postinfusion) and passive avoidance tasks ( 14-1 5
days postinfusion). These behavioral impairments were associated with a moderate
reduction in choline acetyltransferase (ChAT) activity in the frontal cortex (3 and 30
pmol/day) and hippocampus (300 pmol/day). No differences were observed in AChE activity
between treatment groups. Also, ltoh et al. ( 1 56) demonstrated in this model that A~
infusions (300 pmol/day) reduced nicotine stimulated release of acetylcholine and dopamine
determined 11-13 days postoperatively by an in vivo brain microdialysis method.
Furthermore, dopamine release induced by high potassium stimulation was also decreased in

12
these rats. These results suggest that learning deficits in these animals are partly due to the
impairment of neurotransmitter release.
McDonald et al. (223) observed that single bilateral hippocampal injections of Aj3 140 (2 nmol) impaired learning of a signaled footshock avoidance and a food reinforcing task
in a Y-maze, suggesting a detrimental effect of Aj3 on memory consolidation. Chronic daily
Aj3 1-40 injections (0.5 nmol/day) for 26 days had no effects on an eight-arm radial maze
performance, and no aggregation of Aj3 or significant necrosis was observed upon
postmortem histological analysis. These experiments suggest that single injections of Aj3
impair memory consolidation but repeated injections do not affect well-learned behavior. In
a follow-up study (224), these authors sought to determine if the amnesia was specific to
the Aj3 1-40 sequence, and if the amnesia could be attributed to a consolidation process.
The results indicate that the reverse peptide Aj3 40-1 has no behavioral effect, and that Aj3
1-40 injected after partial training does not interfere with a consolidation process.
Cleary et al. (41) showed that acute bilateral hippocampal Aj3 1-40 ( 1-3 nmol)
administrations 20 min before testing did not alter the behavior of rats performing under
stable food-maintained schedules of reinforcement or under a delayed conditional
discrimination procedure. Also, no behavioral changes were observed during chronic 15
days Aj3 1-40 ( 1 nmol/day) injections but lever-pressing performance declined significantly
30 days after termination of the chronic daily regimen. Thioflavin S positive staining,
indicating the presence of Aj3 deposits, was observed in 3 of 6 rats in and around the area
of cannula termination approximately 60 days after the last Aj3 1-40 injection.
Giovannelli et al. ( 102) demonstrated that unilateral injections of Aj3 1-40 (2. 3 nmol)
and Aj3 25-35 (9.4 nmol) into the right nucleus basalis of rats resulted in Congo red positive
Aj3 deposits at the injection site. These deposits were visible for about 21 days in the Aj3
25-35 treated rats and for at least two months in the Aj3 1-40 injected rats. The presence
of these deposits was associated with a reduction in the number of ChA T immunopositive
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neurons in the

A~

25-35 rats at 7 and 14 days postoperatively, and in the

A~

1-40 rats at

7, 14, 21, 30 and 60 days postinjection. This reduction in ChAT IR was paralleled by a
decrease in basal acetylcholine release from the parietal cortex ipsilateral to the lesion.
Disruption of object recognition was observed at 7 and 14 days after
whereas

A~

A~

25-35 injection,

1-40 caused a slight impairment only two months after lesion.

In addition to injections of
bilateral injections of 4 nmol of

A~

A~

alone, a report by Dornan et al. (65) indicated that

25-35 and 6 nmol of ibotenic acid into the rat

hippocampus disrupted acquisition of spatial learning in the radial arm maze 8-32 days
postinjection, whereas

A~

only the combination of

25-35 alone had no effect. Histological examination revealed that

A~

25-35 with ibotenic acid produced a lesion along with focal

deposits in the hippocampus.
We observed that

A~

25-35 (1 or 8 nmol) injected bilaterally into the ventral

pallidum/substantia innominata (VP/SI) of rats failed to produce behavioral, histological or
neurochemical signs of toxicity (314). Also, neither dose of

A~

25-35 potentiated the

effects of quinolinic acid (37 .5 nmol) on behavior or amygdaloid ChAT activity, and did not
appear to increase the histological damage caused by quinolinic acid. These results suggest
that

A~

25-35 is not neurotoxic within the VP/SI and that it does not potentiate the

neurotoxicity of quinolinic acid in the VP/SI.
All the above studies analyzed young animals and injected peptide sequences that
correlate with the human

A~.

In one study by Winkler et al. (354), a rat

A~

1-42 was

injected bilaterally into the hippocampus or the lateral ventricle of 3 month old rats. Fifteen
months later, these rats did not differ from vehicle treated rats in their ability to learn a
spatial memory task in the Morris water maze.

A~

IR was detected at the injection site at

16 months following injection but no qualitative neuronal loss was observed.
In addition to these findings, behavioral effects have also been demonstrated for
amylin, which is a 37 amino acid amyloidogenic peptide of a different sequence than A~.
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Kovacs et al. (175) observed that a unilateral administration of amylin (64-255 pmol) into
the lateral brain ventricle of rats led to an increase in the latency of passive avoidance
behavior, and caused facilitation of the extinction of active avoidance behavior 24 h
postinjection. Amylin also inhibited locomotion in an open field, and increased rearing and
grooming activity during the first 24 h postinjection. According to the authors, these
findings suggest that amylin influences the behavioral reaction in these paradigms mainly by
acting on locomotion, and not by modifying learning and memory processes.

Tau Protein

The main component of neurofibrilllary tangles is paired helical filaments (168,335),
which consist largely of the protein tau in an abnormal state of phosphorylation
(171, 183,355,356). Tau consists of six isoforms of a molecular weight of 55 to 62kD that
are generated by alternative splicing of a single gene (106, 140). Tau is a potent promoter
of tubulin assembly in vitro (43), and is often associated with microtubules in neuronal
axons. However, it is also found normally in the somatodendritic compartments and in glia
(201,232,259). In AD, neurofibrillary tangles are found predominantly in the perinuclear
region encircling the nucleus (231), but prominent tau IR fibers without classical tangle
formation are also found in cell bodies of affected neurons (259). There is a correlation
between the number of cortical tangles and the degree of cognitive impairment (17,289),
and it has been reported that tangles, but not senile plaques, parallel duration and severity
of AD (8). Tau isolated from paired helical filaments is extensively phosphorylated
compared to normal tau but there has also been isolated from AD brain abnormally
phosphorylated non-paired helical filament tau (173). Presently, the kinases that mediate
tau phosphorylation have not been conclusively identified but various kinases have -been
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implicated (67, 151, 152, 194,260,341,345). There may also be alterations in the activities
of certain protein phosphatases in AD (111, 185,215,266), that have been shown to
dephosphorylate tau in vitro (66, 109, 110, 112,294,343). It should be noted, however, that
the significance of the hyperphosphorylated state of tau to the etiology and progression of
AD remains to be determined. Interestingly, intracerebral injection of abnormally
phosphorylated tau proteins purified from AD brains has been shown to enhance

A~

IR in rat

brain (312), suggesting an association between plaque and tangle formation in AD.
Various antibodies recognize tau proteins, such as tau-2 and Alz-50. The tau-2
antibody recognizes tau proteins in both the phosphorylated and non-phosphorylated form.
This antibody does not discriminate between normal tau and hyperphosphorylated
Alzheimer's tau in unfixed tissue, but recognizes only the Alzheimer's tau in fixed tissue
(259). The Alz-50 antibody in immunocytochemical studies stains AD brain tissue (55), but
its IR in normal brain tissue appears to depend on the method used (293). It demonstrates
early changes in AD by recognizing abnormally phosphorylated tau protein (337).

Apolipoprotein E

The gene for ApoE is located on chromosome 19 and is the first known gene that
confers susceptibility for the sporadic late-onset form of AD. The three major alleles of
ApoE are E2, E3, and E4. An increased frequency of the ApoE4 allele is associated with
late-onset AD (325), and leads to an increased number of amyloid plaques compared to AD
cases that do not have this risk factor (280,299). Conversely, the ApoE2 allele decreases
the risk of AD and delays disease onset (49,290). ApoE binds to soluble A~ in vitro (326)
and enhances fibrillogenesis in an isoform specific manner, with ApoE4 being more active
than ApoE3 (205,296,359). These in vitro studies correlate with findings that ApoE is
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associated with amyloid plaques (245,246,280,360). ApoE is found }n the neuronal
cytoplasm (125) and is also associated with neurofibrillary tangles in AD (245,280). It
binds to nonphosphorylated tau in vitro, and ApoE3 binds with higher affinity than ApoE4
(324).

Presenilins

Mutations in three genes account for a portion of cases of the early-onset familial
form of AD. The first of these genes to be associated with AD was the gene for APP on
chromosome 21 . However, mutations in this gene account only for a small fraction of the
early-onset AD cases. The most common mutations are found on chromosome 14
(297, 322), in a gene that encodes the protein presenilin 1 (31 0). This protein appears to be
an integral membrane protein containing seven to nine transmembrane domains. A second
transmembrane protein, presenilin 2, is 67% homologous in amino acid sequence to
presenilin 1 . The gene coding for presenilin 2 is found on chromosome 1 and is the likely
genetic locus of familial AD in Volga German families (192, 193). More than 25 different
inherited mutations have been identified in these two presenilin genes (344). The functions
of the proteins encoded by the presenilins are unknown but they may be localized to the
endoplasmic reticulum and Golgi complex in transfected cells ( 176). This finding suggests
that the presenilins may affect protein transport and/or processing, possibly modulating the
processing of APP and production of

A~.

In support of this scenario, a recent report

indicates that levels of A~ 1-42 and/or A~ 1-43 are increased in fibroblast media and plasma
from carriers of mutations in these genes (298). In addition, increased

A~

1-42 and/or

A~

1-43 levels are found in brains of mice that express mutant presenilin 1 (69).
Overexpression of presenilin 2 in PC 1 2 cells has been demonstrated to increase apoptosis
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induced by trophic factor withdrawal or AP, and a presenilin 2 mutation associated with
familial AD enhances basal apoptotic activity (362).

Glia in Alzheimer's Disease

More than half of the volume of the brain consists of non-neuronal cells (93). The
largest class of these cells are comprised of neuroglia, and there are up to 1 0 times as many
neuroglial cells in the brain as there are neurons. The neuroglia are further categorized as
microglia or macroglia.

Macroqlia: Astrocytes
The majority of the neuroglia are macroglia which are further subdivided into
oligodendrocytes and astrocytes. Astrocytes modulate inflammatory and immune responses
in the CNS, induce and help maintain the blood-brain-barrier, regulate the neuronal
environment, and facilitate neuronal growth, repair and regeneration. The transformation of
resting astrocytes to reactive astrocytes is one of the earliest and most dominant responses
of the CNS to tissue injury. The reactive state is characterized by nuclear changes and a
cytoplasmic enlargement that is associated with the generation of thicker, longer and more
complex processes. In the AD brain, reactive astrocytes are found in high abundance
surrounding senile plaques (70, 126, 128,250). They colocalize with plaques at a relatively
early stage in AD and apparently prior to the appearance of plaque associated dystrophic
neurites (270). Glial fibrillary acidic protein (GFAP) (77) is a component of the glial
intermediate filaments that form part of the cytoskeleton, and is found predominantly in
astrocytes. GFAP levels in AD brains are increased 8 to 16 fold compared to control brains
(21,60).
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There are several possible roles for astrocytes in AD. Reactive astrocytosis may
occur merely as a response to an underlying pathology. Astrocytes may be recruited in an
attempt to attenuate the progression of the disease and/or to enclose degenerating areas
with astrogliotic scar. Astrocytes may also have a causal or contributory role in the
pathology. In this scenario, the primary pathology may be astrocytic and lead to AP
production and/or subsequent events that lead to neuritic damage and tangle formation.
Also, AP may be toxic to astrocytes and that may indirectly lead to neuronal damage.
Recent reports suggest that AP induces reactive astrocytosis in vitro (34, 141,271), but
does not decrease astrocyte viability (271 ).
Excitotoxicity has been hypothesized to have a role in the pathology of AD ( 114).
Glutamate is the major excitatory neurotransmitter in the brain, and the distribution of
plaques in AD correlates well with the termination of glutamatergic fibers (79,264,283).
Both astrocytes and neurons are involved in glutamate transport and metabolism. Glutamate
uptake is primarily performed by astrocytes, both in culture and in vivo (135, 136, 142,229).
AP in some culture systems has been observed to potentiate neuronal excitotoxicity
(170,218). This suggests that the glutamate transporting activity of astrocytes may be
impaired by AP but no reports have investigated this phenomenon. However, AP has been
shown to increase expression of glutamine synthetase (GS) in cultured astrocytes,
suggesting that AP-related reactive astrocytosis in AD may benefit local neurons by
enhancing glial capacity to regulate levels of glutamate (272). Conversely, AP has been
reported to produce a mild but significant impairment in GS activity in mixed cultures (127).
Whether GS levels and activity are affected in AD is unclear (164,319).

Microqlia
Over the last decade several investigators have noted that the AD brain exhibits
many classical markers of immune-mediated damage. Microglia are the brain's
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representatives of the immune system and express many leukocyte surface antigens which
are upregulated in AD (227). In AD, there is a vigorous activation of the classical, but not
the alternative complement pathway (74, 75, 153, 154,225,226). AD lesions are easily
revealed by antibodies to complement factor (C) 1q, C3d, and C4d (225,226). All these
antibodies recognize extracellular amyloid deposits, dystrophic neurites, neurophil threads,
extracellular neurofibrillary tangles, and even some intraneuronal tangles. The components
of the complement pathway may be partly derived from reactive microglia ( 1 23). It is not
known what causes activation of the classical complement pathway in AD, but it is of
interest that

A~

can bind C1 q (304). This interaction activates the classical cascade in vitro

(282), and enhances the cytotoxicity of
~-pleated

A~

(304), likely by increasing

A~

aggregation into a

sheet structure and by stabilizing preformed aggregates (348). In the AD brain,

microglia are known to associate with plaques (122, 155,228). Microglia in culture
scavenge

A~

(5) and microglia-like phagocytes have a role in

intraventricular infusions of

A~

(92). However,

A~

A~

clearance following

can induce degeneration of cultured

microglia (174).
Cytokines are polypeptides with diverse actions on many cell types, and are
particularly important as mediators of inflammation and regulation of cell growth and
differentiation. The cytokines are generally classified into four groups; the interleukins,
tumor necrosis factors, interferons, and growth factors. Inflammatory cytokines found in
senile plaque regions include interleukin (IL) 1, IL-6, and tumor necrosis factor
(62, 117,309). Microglia seems to be the major source of IL-1 within the CNS, but this
cytokine is also found in astrocytes and neurons (300). In rat, mouse, human and other
species, IL-1 exists in two forms, IL-1a (199) and IL-1 ~ (9), that are the products of two
separate genes (40,97). Human IL-1 a and IL-1 ~ have 25% homology and appear to have a
similar biological activity (63). IL-1 ~in vitro stimulates the APP promoter (64), induces APP
mRNA (59,89, 108), stimulates APPs secretion (31 ), and enhances A~ cytotoxicity in PC12
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cells (82). AP in vitro induces IL-1 P mRNA in astroglial cells (59), enhances astro- and
microglial secretion of IL-1 (4), and stimulates the proliferation and morphological
transformation of microglia (4). AP also increases nitric oxide production from microglial
cells in culture but not from astrocytes or cortical neurons. This production is potentiated by
the cytokine interferon-y and leads to an injury of cortical neurons (149). Furthermore, the
synergistic activation of cultured microglia by AP and interferon-y causes the production of
neurotoxic free radicals (230).

Distribution of Alzheimer's Disease Pathology

Individuals with Down's syndrome (trisomy 21) invariably develop the
neuropathological hallmarks of AD (23, 187). Therefore, it is likely that the sequence of
pathogenic alterations in Down's syndrome resembles that of AD. Overexpression of APP
mRNA has been observed in Down's syndrome brains (248,291), and senile plaques appear
at a younger age than do neurofibrillary tangles in Down's syndrome ( 100,212,291,358),
suggesting that AP may have a role in tangle formation. In AD, the distribution of plaques
and tangles suggests that neurons that have efferent projections to areas that contain
amyloid deposits often contain tangles (265). For example, senile plaques accumulate
within the amygdala in the terminal zone of tangle bearing hippocampal neurons ( 1 81). This
suggests that AP may act on nerve terminals to cause cytoskeletal alterations in axons that
ultimately lead to tangle formation within the perikarya (265). This notion is supported by
the observation that the APP is predominantly located in the synaptic zone of neurons
(301). Therefore, deposition of AP fibrils and their initial toxic effects would primarily occur
near their site of generation, namely at the nerve terminals. These effects then would
gradually spread to distal brain regions that send axons to the area of initial deposition.
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However, there are areas severely affected by neurofibrillary tangles whose projection zone
is not frequently affected by senile plaques (279). For example, subicular/CA 1 hippocampal
neurons develop tangles and project strongly to layer IV of the entorhinal cortex, which
contains tangles but few senile plaques ( 14 7). The pathological process in AD occurs over
decades. It is possible that different regions and/or cell types of the brain have different
kinetics for the development and/or degradation of neurofibrillary tangles and senile plaques.
The major pathological changes in AD are in regions of the medial temporal lobe,
including the hippocampus, amygdala, entorhinal cortex and parahippocampal gyrus (265).
Within these brain regions, the number of senile plaques has been reported to be highest in
the amygdala (8). Some reports indicate that the amygdala is affected earlier in the disease
than the hippocampal or cortical areas (158,258). Severe ChAT deficits have been reported
in the amygdala in cases of histopathologically confirmed AD with no significant deficits in
the neocortex or hippocampus (258). Also, in at least one AD case report, senile plaques
and neurofibrillary tangles were almost exclusively restricted to the amygdala ( 1 58). The
presence of numerous senile plaques without neurofibrillary tangles in the amygdala of a 1 9
year old patient with Down's syndrome suggests that the amygdala is a focus of early
pathological changes in Down's syndrome and possibly AD (243). In patients with Down's
syndrome between the ages of 35-45, many classic senile plaques are found in the
amygdala but neocortical senile plaques are sparse and usually primitive, and neurofibrillary
tangles are rare (208-210). A study (211) of non-demented patients of all ages showed the
greatest severity of senile plaques primarily within the amygdala, whereas neurofibrillary
tangles were found predominantly within the hippocampus.
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Laterality in Alzheimer's Disease

The human brain is asymmetric, as are the brains of other animals. Although the left
hemisphere is significantly different in function from the right, there appears to be no
structure or chemical constituent that is present in one hemisphere but not in the other.
However, there are quantitative differences between the hemispheres that may lead to
qualitative differences. Asymmetry has been observed in neurotransmitter, neuroendocrine,
and neuroimmunologic activity (361 ).
Some investigators have demonstrated lateralization in the involvement of the rat
amygdala in learning and memory (15,45-47), and lesions of various brain regions in rats
(36,61, 121, 184,262,281,329,342) and mice (10) have asymmetrical effects. Ligation of
the right middle cerebral artery has been shown to lead to hyperactivity and reductions in
norepinephrine and dopamine, whereas ligation of the left middle cerebral artery has no
behavioral or neurochemical effects (281). Also, occlusion of the left or right middle
cerebral artery has different effects on mean arterial pressure, renal sympathetic nerve
discharge, and plasma norepinephrine levels ( 1 21). Suction lesions of the right frontal
cerebral cortex induce hyperactivity (61,262), that is accompanied by a bilateral decrease in
norepinephrine concentrations (262). However, identical lesions of the left cortex do not
produce hyperactivity (61,262) or a decrease in norepinephrine concentrations (262). Left
cortical ablations affect mainly the activity of serotonergic inputs to the right neocortex,
whereas ablations of the right cortex influence the activity of the catecholaminergic inputs
to the left cortex ( 10). Ablations of the prefrontal or parietal cortices lead to lateralized
brain immunomodulation (342). Kainic acid injections into the right frontal cortex produce a
significantly greater hyperactivity than identical injections into the left hemisphere ( 1 84).
Striatal lesions with 6-hydroxydopamine lead to greater dopamine depletion in right-lesioned
rats than in left-lesioned rats (329). Also, left and right 6-hydroxydopamine lesions of the
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medial prefrontal cortex differentially alter subcortical dopamine utilization and the behavioral
response to stress (36).
Asymmetries have been observed in the histopathological hallmarks (52,235), and in
the reductions in ChAT activity (235,287) in individual cases of AD, but preferential
involvement of either hemisphere has not been demonstrated in groups of AD patients.
Interestingly, asymmetry in the density of senile plaques diminishes with increasing
neuropathological severity (235), suggesting that laterality may be more prominent in the
initial stages of the disease. In AD, there is an extensive neuronal loss and shrinkage in all
subdivisions of the amygdala (340), but no left-right hemispheric differences were detected
in total neuron numbers in a study of 9 AD cases (340). However, hemispheric laterality in
cerebral metabolism and perfusion in AD has been demonstrated in several studies. In most
of these reports, there is no directional preference in asymmetry (37,68,95, 113, 129132,254), whereas some findings indicate preferential involvement of the left (197,306) or
the right hemisphere (239). Early onset cases of AD have been associated with a greater
prevalence of left (247,306) or right (148) hemispheric dysfunction compared to late onset
AD cases. Other studies have found no correlation between asymmetry in hemispheric
dysfunction and the duration or severity of the illness (197,239), suggesting that laterality in
AD reflects subtypes more than the evolution of the disease.

Animal Models for Alzheimer's Disease

There is a loss of cholinergic neurons in the basal forebrain in AD, that contributes
to the amnestic deficits observed in the disease (12,57,351 ).

The early animal models of

AD attempted to mimic the degeneration of the basal forebrain cholinergic neurons by
lesioning the nucleus basalis magnocellularis (84, 134, 195) and/or the medial septal. area
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( 1 34). This approach was limited as a model of AD because it lacked the broad spectrum of
pathological features of the disease. Neurons producing norepinephrine, serotonin,
dopamine, glutamate, y-aminobutyric acid, somatostatin, neuropeptide Y, corticotrophin
releasing factor, substance P, and other neuromodulators are also affected in AD
(54,56, 157, 177,288,327). Because of these broad deficits in neurotransmitter systems, it
is unlikely that AD can be treated by transmitter replacement therapy alone. A more feasible
approach is to develop compounds that interfere with neuritic plaque and tangle formation,
the major histopathological hallmarks of the disease.
The discovery of

A~

as a major component of senile plaques and subsequent

findings of its in vitro neurotoxicity led to model approaches examining the direct effects of
A~

in vivo by microinjection of

Effects of

A~

A~

into the brains of rats and monkeys (see

Peptides on Behavior). The reproducibility of

A~

A~

Peptides and

toxicity in vivo has been

inconsistent (42,91,99, 101, 102, 178, 180,314,320,354). This may be due to variations in:
1) the conformational state (25,269,273), dose, and sequence of

A~;

2) method of

administration; 3) pathological endpoints measured; 4) what brain region and/or hemisphere
is injected; 5) postoperative interval; and, 6) species and/or strain used. Therefore, further
studies on the in vivo effects of

A~

are warranted.

Various transgenic approaches toward an animal model for AD have recently been
described. The approaches differ in several aspects such as: 1) in the selection of a
promoter to drive APP expression; 2) in the isoform or segment of APP expressed; 3) in the
strain of mouse used; and, 4) in the age of the animals at the time of behavioral testing
and/or histological analysis.
AB Transgene: Overexpression of mouse

A~

in mice by LaFerla et al. (186) resulted in

extensive neuronal apoptotic degeneration and reactive astrogliosis without any evidence of
amyloid deposition or neurofibrillary pathology. The mouse

A~

was selected in case an
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interaction with species specific factors was required for its toxicity. These animals had
approximately half the lifespan of normal mice and some of them developed seizures.
APP Transqenes: Approaches using full length mouse or human APP can be divided into
three groups: 1) expression of normal individual APP isoforms; 2) expression of individual or
several APP isoforms that carry mutations that have been associated with AD; and, 3)
generation of mice transgenic for the intact APP gene.
The initial report on behavioral impairments in transgenic APP mice by Yamaguchi et
al. (364) demonstrated that mice expressing the normal human APP695 isoform had
impaired spatial memory in the Morris water maze. Training commenced when the mice
were 8 weeks old and behavioral testing continued until the animals were 20 weeks old at
which time they were sacrificed for histological analysis. These animals were significantly
retarded in initial learning and in learning a new escape location, but they eventually reached
control levels. However, these mice also had slower swimming speed and reduced
nocturnal activity, that may have contributed to their deficit in spatial learning. No

A~

deposits were observed in these mice, and no neuropathological hallmarks of AD have been
detected in this same transgenic line at 1-3 years of age. The authors suggest that gene
dosage effect of APP695 may account for the memory impairment. The authors also raise
the question of whether insertion of multiple copies of any gene construct may impair
cognitive function, because inheritance of relatively small amounts of extra genomic DNA in
human imbalanced translocation karotypes results in mental retardation.
Czech et al. (53) showed that transgenic mice containing the three major neuronal
isoforms for the normal human APP, that is APP695, APP751, and APP770, expressed the
transgenic APP in several tissues including brain but expression levels never exceeded those
of the endogenous mouse APP (53). No pathological changes resembling those of AD and
Down's syndrome were observed in these animals. However, the mice transgenic for
APP695 showed an impairment in a spatial navigation task, and the mice transgenic for
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APP751 showed deficits in motor performance. The authors of this study stress that it is
not clear whether these behavioral effects are due to the expression of the transgene or to
position effect of transgene integration.
Hsiao et al. ( 146) demonstrated that transgenic mice overexpressing normal human
or mouse APP695 died usually within a year and developed a CNS disorder that included
neophobia and impaired spatial alternation, with diminished glucose utilization and
astrogliosis mainly in the cerebrum. Human APP transgenes induced death much earlier
than mouse APP transgenes expressed at similar levels. No extracellular amyloid was
detected, indicating that some deleterious processes related to APP overexpression are
dissociated from formation of amyloid.
Transgenic mice expressing normal human APP751 have been shown by Higgins et
al. (137, 138) and Quon et al. (277) to develop diffuse AP deposits and rarely an induction in
Alz-50 IR, particularly in the hippocampus, cortex, and amygdala. The AP deposits were not
Congo red positive and lacked neuritic involvement. Because the deposits did not show
birefringence under polarized light when stained with Congo red, they did not have the Ppleated sheet structure of AP that is found in senile plaques. These histopathological
changes increased somewhat in frequency with aging (139). These mice also exhibited age
dependent deficits in spatial learning in a water maze task and in working memory in
spontaneous alternation in a Y maze (236). Interestingly, these transgenic mice also
exhibited a greater latency in locating a visible platform in the water maze. This suggests
that vision impairment may account for differences in performance. These deficits were
mild or absent in 6 month old mice but were severe in 12 month old mice compared to agematched wild-type control mice. Neither age group of the transgenic APP751 mice showed
any changes in string test, rotarod, plus maze, or circadian variation in spontaneous activity.
These findings show that these mice did not have any gross motor, physiological or
behavioral impairments that may have confounded interpretation of the learning tasks.
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These mice may model the progressive learning and memory impairment that is a cardinal
feature of AD, but further tests are necessary to investigate possible vision impairments.
The discovery of the association of AD with inherited APP mutations led to the
development of transgenic mouse models containing these mutations. Malherbe et al. (206)
reported that transgenic mice expressing various familial AD missense mutations, that were
maximally 1.3 fold of those of wild-type mouse APP, showed no AD-like pathology and had
no behavioral impairments. However, recently two mouse models have been described by
Games et al. (98) and Hsiao et al. (145), that contained age dependent compact congophilic
A~

plaques similar to those observed in AD, and in one of these models these changes were

associated with behavioral impairments (145). The first of these models to be described
overexpressed APP containing the APP717 mutation that is associated with familial AD
(98). These mice expressed 8-1 0 fold the normal level of APP and had large numbers of
amyloid plaques in the hippocampus, corpus callosum, and cerebral cortex that first
appeared at 6-9 months of age. The majority of the plaques were associated with reactive
astrocytes and dystrophic neurites. The neocortices of these mice exhibited diffuse synaptic
and dendritic loss, and contained diffusely activated microglia. This histopathology was
region specific and age dependent as in AD, despite expression of the APP transgene
throughout the brain. These results suggest that region and/or cell type specific
vulnerability of the aging brain may dictate the pattern of plaque formation. A significant
limitation of this model is the lack of neurofibrillary tangles, and their absence may reflect
species variations in neuronal response to injury. Also, in this model there have been no
reports of behavioral impairments associated with the histopathological changes.
The other promising transgenic mouse model (145) overexpressed a mutated form of
APP695, that has been found in a Swedish family with early-onset AD (242). These mice
expressed this human form at 5-6 fold the levels of endogenous mouse APP, that remained
unchanged between 2 and 14 months of age. These mice demonstrated normal learning
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and memory in the Morris water maze and the Y maze at 3 months of age but were impaired
by 9 to 10 months of age. A five fold increase in A~ 1-40 and a 14 fold increase in A~ 142 was associated with these behavioral deficits. Numerous Congo red positive
were present in mice with elevated

A~

A~

plaques

levels. The distribution of the histopathological

changes was reportedly similar to that observed by Games et al. (98). Although the authors
indirectly control for impairments in motor performance, it is possible that the behavioral
impairments may be caused by visual impairments. This possibility, overlooked by the
investigators, is based on the impairment of the transgenic mice in swimming to a visible
platform.
In contrast to other APP transgenic models, the expression of human APP variants in
these two promising models (98, 145) substantially exceeds those of the endogenous mouse
APP gene. Because of the various proposed roles for APP, it is likely that 5-10 fold increase
in APP has several biological effects besides causing an increase in

A~

production and

subsequent plaque formation. It is also possible that insertion of multiple copies of any
gene construct may impair cognitive function, because inheritance of relatively small
amounts of extra genomic DNA in human imbalanced translocation karotypes results in
mental retardation. The behavioral effects may also be due to position effect of transgene
integration that may interfere with the expression of other genes.
The complete human APP gene has also recently been introduced into mice by Lamb
et al. (188) and Pearson et al. (263). Both sets of mice properly spliced human APP mRNA
in their brains to generate the three major isoforms of APP, APP695, APP751, and APP770,
but in hemizygotes their expression levels were below those of the endogenous mouse APP.
No signs of AD-type pathology has been observed (188) or reported (263) in these mice.
These mice may overexpress human APP once they have been bred to homozygosity.
Even though several in vitro studies have tested various hypotheses for the
mechanism by which

A~

exerts its toxic effect, these hypotheses have not been adequately
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assessed in in vivo situations. It is important to continue to explore the in vivo effects of
AP by direct injections into brain. Findings from these studies may help elucidate the
sequence of pathogenic events that ultimately lead to AD. They may also distinguish
between the biological effects of AP and elevated levels of APP, respectively. There are
several advantages associated with the injection approach. For example, it is substantially
less expensive. The pathology appears to peak at an earlier timepoint than in transgenic
animals, thereby reducing the time required for drug screening. Furthermore, the pathology
is due to AP, but in the transgenic animals some of the pathology may be due to effects of
elevated levels of APP and/or due to position effect of transgene integration. For example,
the site of transgene integration is thought to be random and its location may affect the
expression of other genes. Therefore, injection models may give a clearer picture than
transgenic models of the role of AP in the progression of AD.

CHAPTER II
AIMS OF THE PRESENT STUDY

Puroose

Because the early and primary histopathological changes in Alzheimer's disease (AD)
are predominantly found in temporal lobe structures, it was determined if injections of
amyloid-P (Ap) 25-35 into the amygdala of the rat can induce the appearance of abnormal
conformations of tau proteins and reactive astrocytes as seen in AD. It also was examined
whether the effects of AP were time dependent and included neuronal shrinkage, cell loss
and/or microglial activation. Finally, it was determined whether the histological effects of
AP were associated with alterations in choline acetyltransferase (ChAT) activity and/or
behavioral changes. Thus, the overall objective of this project was to develop an animal
model for AD.

Overall Hypothesis: In vivo injections of AP will induce the appearance of abnormal
conformations of tau proteins and reactive astrocytes as seen in AD. The effects of AP will
be time dependent and include neuronal shrinkage, neuronal loss and microglial activation.
Furthermore, these histological changes will be associated with neurochemical and
behavioral alterations.

Specific Aim 1: To determine the histological effects of unilateral intra-amygdaloid injections
of AP 25-35 (5.0 nmol) in young rats at 8 and 32 days postoperatively.
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Hypothesis:

A~

will induce conformational changes in tau proteins. These changes will be

associated with reactive astrocytosis, neuronal shrinkage and cell loss.

Methods: Cresyl violet, tau-2, Alz-50 and GFAP staining

Rationale:
The histopathological characteristics of AD include neurofibrillary tangles, senile
plaques, reactive astrocytes, neuronal shrinkage, and cell loss in several brain regions. The
main component of the neurofibrillary tangles is paired helical filaments ( 168,335), which
consist largely of the microtubule associated protein tau in an abnormal state of
phosphorylation (171, 183,355,356). In the AD brain, reactive astrocytes are associated
with senile plaques (70, 126, 128,250). Senile plaques consist predominantly of

A~

1-42

peptide ( 103,214,233,285), which is derived from a large membrane spanning protein, the
amyloid-~

precursor protein (APP) (166). Mutations in APP in some forms of familial AD are

associated with an elevated production of

A~

(33,39,331 ). APP is overexpressed in

Down's syndrome (248,291 ), and individuals with this disease invariably develop the
neuropathological hallmarks of AD (23, 1 87). The proposed role for
of AD is further supported by the neurotoxicity of

A~

A~

in the pathogenesis

in vitro (369,370), which includes

amino acids 25-35 of the peptide (370).
The reproducibility of

A~

toxicity in vivo has been inconsistent

(42,91,99, 101, 102, 178, 180,314,320,354). This may be due to variations in: 1) the
conformational state (25,269,273), dose, and sequence of

A~;

2) method of administration;

3) pathological endpoints measured; 4) what brain region and/or hemisphere is injected; 5)
postoperative interval; and, 6) species and/or strain used. Therefore, further studies on the

in vivo effects of

A~ are warranted.
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Recently a direct association between plaque and tangle formation in AD has been
demonstrated by a few studies. In vitro studies have

demonstrc~ted

that AP increases tau

protein kinase I (TPK I) activity (332), induces abnormal tau immunoreactivity (IR) (26,207),
and that the neuronal death caused by AP can be prevented with TPK I antisense
oligonucleotides (332). These findings suggest an association between plaque and tangle
formation in AD. A few in vivo studies have investigated the effects of AP injected into the
central nervous system on tau IR (42,91,99, 178, 180,274). Some of these studies indicate
that AP can induce the appearance of abnormal tau proteins in the vicinity of the injection
site (rat cerebral cortex and hippocampus) (91, 178, 180). Other studies have failed to show
any effect (42,99,274). For the most part, these in vivo studies have only been qualitative
or descriptive in nature. No attempts have been made to quantify AP induced effects by
counting neuronal tau IR cells.
AP has been shown to increase intracellular calcium (7,218). Calcium influx in
cultured rat hippocampal neurons caused by glutamate or a calcium ionophore induces tau
IR as recognized by the antibodies Alz-50 and 5E2 (216). Protein kinases are generally
activated by increases in intracellular calcium and several of those have been shown to
phosphorylate different sites on tau proteins (238). Therefore, AP may increase the
phosphorylation of tau proteins through an activation of kinases mediated by an increase in
intracellular calcium. The activities of some phosphatases that may dephosphorylate tau
proteins have been shown to be decreased in AD (111,311 ). Therefore, AP 25-35 may also
be decreasing the dephosphorylation of tau proteins through an inhibition of phosphatases.
Because of the proposed role for AP in the pathogenesis of AD, intracerebral
injections of AP may induce the pathological changes that occur in AD. It can be argued
that because AP 1-42 is the most prevalent form of AP in senile plaques, it is appropriate to
use that peptide for injections into brain instead of AP 25-35. However, the main problem
with using AP 1-42 is its insolubility in physiological solvents. Therefore, there is a risk of

33
potentially toxic solvents interfering with the properties and effects of
other hand,

A~

25-35 is readily soluble in H 2 0 and acquires the same

A~

1-42. On the

~-pleated

sheet

conformation as A~ 1-42, which is the toxic conformation of A~.
The amygdala was chosen as a region for

A~

injections because it may be affected

earlier in AD than hippocampal or cortical areas (158,258). The major pathological changes
in AD are in regions of the medial temporal lobe, including the hippocampus, amygdala,
entorhinal cortex and parahippocampal gyrus (265). Within these brain regions, the number
of senile plaques has been reported to be highest in the amygdala (8). Individuals with
Down's syndrome invariably develop the neuropathological hallmarks of AD (23, 1 87). The
presence of numerous senile plaques without neurofibrillary tangles in the amygdala of a 1 9
year old patient with Down's syndrome suggests that the amygdala is a focus of early
pathological changes in Down's syndrome and possibly AD (243). In patients with Down's
syndrome between the ages of 35-45 many classic senile plaques are found in the amygdala
but neocortical senile plaques are sparse and usually primitive, and neurofibrillary tangles are
rare (208-210). There have been no previous reports on in vivo injections of

A~

into the

amygdala.
Unilateral injections were employed to determine if

A~

induces histopathological

alterations both ipsi- and contralaterally. The time of sacrifice (8 and 32 days) and the dose
of

A~

(5.0 nmol) were chosen because preliminary results in our laboratory indicated that

these parameters were associated with tau IR adjacent to the injection site in the median
raphe nucleus. Neuronal shrinkage and neuronal loss are one of the hallmarks of AD.
Cresyl violet staining was used in the present study to observe these histological changes.
The tau-2 antibody reacts exclusively with tau proteins in both the phosphorylated and nonphosphorylated form. This antibody does not discriminate between normal tau and
hyperphosphorylated Alzheimer's tau in unfixed tissue, but recognizes only the Alzheimer's
tau in fixed tissue (259), and was therefore used in the present experiment. The Alz-50
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antibody was also used to detect AD-like tau proteins. Alz-50 stains AD brain tissue (55),
but its IR in normal brain appears to depend on the method used (293). It demonstrates
early changes in AD by recognizing abnormally phosphorylated tau protein (337). Although
the epitope that Alz-50 recognizes may not be phosphorylated, the overall peptide
conformation recognized by the antibody may be phosphorylation dependent
(105, 182,337).
Using one antibody that recognizes abnormal tau proteins is not sufficient to
determine if AP can induce the appearance of AD-like tau proteins. The temporal sequence
leading to abnormal phosphorylation and/or conformational changes in tau proteins is not
known. It is possible that AP may be inducing early changes in tau proteins that are not
detected by both the tau-2 and Alz-50 antibodies. These two antibodies recognize different
conformation dependent epitopes on tau proteins. AP may be inducing multiple
conformational changes in tau proteins, which are differently stained using these two
antibodies. The nature and extent of these conformational changes may be time dependent,
brain region specific, and differ within the neuronal structure.
GFAP (77) is a component of the glial intermediate filaments that form part of the
cytoskeleton, and is found predominantly in astrocytes. GFAP levels in AD brain are
increased 8 to 1 6 fold compared to control brains (21, 60). Staining with an antibody
against GFAP was performed to determine 1) if AP increases the appearance of reactive
astrocytes, as seen surrounding senile plaques in AD, and 2) if there appears to be a
correlation between the location and severity of tau-2 and GFAP IR.

Specific Aim 2: To determine the histological effects of bilateral intra-amygdaloid injections
of AP at 8, 32, 64, 96 and 128 days postoperatively.
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Hypotheses: 1) The histological effects of AP will increase with time; and, 2) will be
potentiated by bilateral administration due to the inability of the intact side to compensate
for the contralateral insult.

Methods: Cresyl violet, Congo red, tau-2, GFAP and IL-1 p staining.

Rationale:
The overall objective of this project was to develop an animal model for AD.
Therefore, it was necessary to know how long the effects of AP lasted to prepare for
screening of drugs that prevent, reduce or reverse the histopathological effects of AP. AD
is a bilateral disorder and bilateral infusions are required to determine if the effects of AP are
exponential and for behavioral analyses. To prepare for behavioral experiments, it was
necessary to perform a time course study on the histological effects of AP. The detrimental
effects had to last throughout the behavioral experiments, which typically are performed 4-6
weeks postoperatively. Congo red staining was performed to determine if the AP deposits
within the rat amygdala were of the p-pleated sheet structure that is observed in senile
plaques in AD. Microglia appear to be the major source of IL-1 within the CNS (300). In
the AD brain, microglia are known to associate with plaques (122, 155,228), and
inflammatory cytokines found in senile plaque regions include IL-1 p (62). Thus, staining
was performed on brain sections with an IL-1 p antibody to determine if the intra-amygdaloid
AP deposits were associated with microglia.

Specific Aim 3: To determine if bilateral intra-amygdaloid injections of AP affect ChAT
activity within the amygdala at 32 days postoperatively.

Hypothesis: AP injected into the amygdala reduces ChAT activity within the amygdala.
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Methods: Measurements of ChAT activity.

Rationale:
The amygdala receives a prominent cholinergic input from the nucleus basalis
(35,363), and ChAT activity has been reported to be severely reduced within the amygdala
in AD patients (258,287,288). Measurements of amygdaloid ChAT activity were performed
to investigate if the cytoskeletal changes and neuronal shrinkage within the amygdala were
associated with a reduction in ChA T activity. The time of sacrifice was based on the results
of the time course study that indicated that the histological effects of AP peak at 32 days
postoperatively. Although neuronal loss may not be severe following intra-amygdaloid
injections of AP, this compound may affect the metabolic integrity of cholinergic neurons
projecting to the amygdala. The neurochemical changes in AD that best correlate with the
severity of dementia are reductions in ChA T activity in temporal lobe structures (268).
Thus, ChAT activity was measured within the amygdala.

Specific Aim 4: To determine if bilateral intra-amygdaloid injections of AP cause behavioral
changes that may simulate those observed in AD.

Hypothesis: Bilateral intra-amygdaloid injections of AP will cause behavioral changes at 3452 days postoperatively, that may simulate those observed in AD.

Methods: Open field, one-way active avoidance and Morris water maze.
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Rationale:
Electrolytic lesions of the amygdaloid complex (51,73, 163,305), lesions of the
central nucleus (118, 160,350), or of the lateral and basal nuclei of the amygdala (159)
enhance exploratory behavior of rats in the open field test. Furthermore, lesions of the
amygdala have been shown to be associated with behavioral impairments in active
avoidance learning (30,286), but do not appear to impair spatial learning in the Morris water
maze (58,330). Lesions of the hippocampus severely disrupt spatial learning (257,278),
and this impairment has been shown to be potentiated by amygdaloid lesions (1,267).
Therefore, because intra-amygdaloid injections of

A~

induced histopathological changes not

only within the amygdala but also within the hippocampus, it was considered appropriate to
use the water maze test. The time interval for behavioral testing (34-52 days
postoperatively) was based on the severity of the histological effects observed in the time
course study.

CHAPTER Ill

LOCAL AND DISTANT HISTOPATHOLOGICAL EFFECTS OF UNILATERAL INJECTIONS OF
AMYLOID-~ 25-35 INTO THE AMYGDALA OF YOUNG MALE FISCHER RATS

Abstract

To determine if

amyloid-~ (A~)

astrocytosis in vivo, we injected

A~

induces tau-immunoreactivity (IR) and reactive

25-35 (5.0 nmol) into the right amygdala of rats. At 8

days postinjection, the peptide induced tau-2 IR in neuronal cell bodies and processes
ipsilaterally in the amygdala, cingulate cortex and hippocampus. At 32 days postinjection,
the intensity of tau-2 IR was greater than at 8 days in the amygdala and hippocampus, but
not in the cingulate cortex. Induction of Alz-50 IR also was progressive but the morphology
and distribution was different from tau-2 IR. Beaded fibers with occasional neuronal
perikarya were visualized with Alz-50, and the IR was primarily observed in the ipsilateral
amygdala. In addition, amygdaloid injections of

A~

25-35 induced reactive astrocytosis,

particularly in the ipsilateral hippocampus at 32 days postoperatively.
To our knowledge, this is the first study to show that in vivo injections of

A~

25-35

induce progressive transsynaptic cytoskeletal and astrogliotic reactions, that gradually
spread from the area of injection to brain regions that have prominent efferent connections
with the injected area. These findings also suggest a direct association between plaque and
tangle formation in Alzheimer's disease.
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Introduction

Alzheimer's disease (AD) is characterized histopathologically by amyloid deposition
(senile plaques), neurofibrillary tangles and neuronal cell loss in several, but not all cortical
and subcortical regions. The main component of senile plaques is the amyloid-P (AP)
peptide (103,214,233,285). It is derived from a large transmembrane protein, the amyloid-

p precursor protein

(APP) ( 1 66) and is thought to play an important role in the pathogenesis

of AD. Mutations in the APP gene on chromosome 21 are associated with a subpopulation
of familial AD patients ( 1 04). The main component of neurofibrillary tangles is paired helical
filaments (168,335), which consist largely of the microtubule associated protein tau in an
abnormal state of phosphorylation (171, 183,355,356).
In AD, the distribution of plaques and tangles within subcortical nuclei suggests that
neurons that have efferent projections to areas that contain amyloid deposits often contain
tangles (265). Therefore, since diffuse AP deposition precedes the development of
neurofibrillary pathology ( 1 79), it has been hypothesized that AP acts on nerve terminals to
cause cytoskeletal alterations in axons that ultimately lead to tangle formation within the
perikarya (265). Individuals with Down's syndrome (trisomy 21) invariably develop a
neuropathology indistinguishable from AD (23, 187). Therefore, it is likely that the sequence
of pathogenic alterations in Down's syndrome resembles that of AD. Researchers have
noted that senile plaques appear at a younger age than do neurofibrillary tangles in Down's
syndrome (100,212,291,358), suggesting that AP may have a role in tangle formation.

In vitro studies indicate that AP has neurotrophic (353,370) as well as neurotoxic
(369,370) properties. The in vitro neurotoxic activity includes amino acids 25-35 of the
peptide (370). The reproducibility of AP toxicity in vivo has been inconsistent
(42,91,99, 101, 102, 178, 180, 191,274,314,320,354). This may be due to variations in the
conformational state of AP (25,269,273), different biochemical and/or pathological
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endpoints measured. In vitro studies have demonstrated that

A~

increases tau protein

kinase I (TPK I) activity (332), induces abnormal tau immunoreactivity (IR) (26,207), and
that the neuronal death caused by

A~

can be prevented with TPK I antisense

oligonucleotides (332). There have been a few in vivo studies investigating the effects of
A~

injected into the central nervous system (CNS) on tau IR (42,91,99, 178, 180,274).

Some of these studies indicate that

A~

can induce the appearance of abnormal tau proteins

in the vicinity of the injection site (rat cerebral cortex and hippocampus) (91, 178, 180).
Other studies have failed to show any effect (42,99,274). For the most part, these in vivo
studies have only been qualitative or descriptive in nature regarding effects on tau IR. No
attempts have been made to quantify

A~

induced effects by counting neuronal tau IR cells.

In the AD brain, reactive astrocytes are found in high abundance surrounding senile
plaques (70, 126, 128,250). Glial fibrillary acidic protein (GFAP) is a component of the glial
intermediate filaments that are found in the cytoplasm of astrocytes and form part of the
cytoskeleton. GFAP levels in AD brains are increased 8 to 16 fold compared to control
brains (21,60).

A~

has been shown to induce a reactive phenotype in cultured astrocytes

but does not decrease astrocyte viability (271 ).
The major pathological changes in AD are in regions of the medial temporal lobe,
including the hippocampus, amygdala, entorhinal cortex and parahippocampal gyrus (265).
Some reports indicate that the amygdala is affected earlier in the disease than the
hippocampal or cortical areas ( 1 58,258). Severe choline acetyltransferase (ChAT) deficits
have been reported in the amygdala in cases of histopathologically confirmed AD with no
significant deficits in the neocortex or hippocampus (258). Also, in at least one AD case
report, senile plaques and neurofibrillary tangles were almost exclusively restricted to the
amygdala ( 1 58). The presence of numerous senile plaques without neurofibrillary tangles in
the amygdala of a 1 9 year old patient with Down's syndrome suggests that the amygdala is
a focus of early pathological change in Down's syndrome and possibly AD (243). In
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patients with Down's syndrome between the ages of 35-45 many classic senile plaques are
found in the amygdala but neocortical senile plaques are sparse and usually primitive, and
neurofibrillary tangles are rare (208-210). A study of non-demented patients of all ages
showed the greatest severity of senile plaques primarily within the amygdala, whereas
neurofibrillary tangles were found predominantly within the hippocampus (211).
Because the primary and early histopathological changes in AD are found primarily
within temporal lobe structures, we determined if a unilateral

A~

25-35 injection into the

amygdala of the rat can induce the appearance of abnormal microtubule associated protein
tau and reactive astrocytes as seen in AD. Secondly, we examined whether brain areas that
project to and/or receive projections from the amygdala showed similar changes, and how
long these effects last.
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Materials and Methods

Animals
Male Fischer-344 rats were obtained from Harlan Sprague-Dawley Inc. (Indianapolis,
IN). At the time of arrival, the rats weighed 250-300 g and were 3-4 months of age. The
animals were housed individually, maintained on a 12 h light-dark cycle (lights on at 07:00
h) in a AAALAC approved facility, had access to food and water ad libitum, and were
habituated to their new environment for 2-3 weeks prior to surgery.

Surgery
Surgery was performed under sodium pentobarbital (50 mg/kg, intraperitoneally
(i.p.); Butler, Columbus, OH) anesthesia. Atropine sulfate (0.4 mg/kg; Sigma, St. Louis,
MO) and ampicillin sodium salt (50 mg/kg; Sigma) were injected intramuscularly once the
animals were anesthetized. The animals received a unilateral injection into the right
amygdala. A Kopf stereotaxic instrument was used with the incisor bar set at 3.3 mm
below the interaural line. Injection coordinates measured from bregma and the surface of
the skull (AP - 3.0, ML - 4.6, DV - 8.8) were empirically determined based on the atlas of
Paxinos and Watson (261). The anteroposterior (AP) coordinate was positioned where the
amygdaloid structure is largest. The mediolateral (ML) coordinate was centered between the
medial and lateral aspects of the amygdala (medial to the basolateral nucleus). The
dorsoventral (DV) coordinate was centered between the dorsal and ventral aspects of the
amygdala. A volume of 3.0 µI was administered over 6 min (flow rate 0.5 µI/min) using a
CMA/100 microsyringe pump (Carnegie Medicin AD, Solna, Sweden). The cannula was left

in situ for 2 min following injection, and then was slowly withdrawn. Following surgery the
animals were placed on a heating pad until they regained their righting reflex.
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Most of the previous studies which have injected

A~

into the brain have utilized a

volume of 1.0 µI or less. The choice of an appropriate volume must be based on the
physiochemical properties of the substance, outside and within the brain. It has been
reported that

A~

25-35 at high concentrations (10 nmol/µI) forms a viscous gel (292), and

may therefore adhere to the cannula resulting in an inaccurate dose delivery and spread of
the peptide along the cannula track. In addition,

A~

25-35 appears to aggregate at the site

of injection and does not diffuse from the vicinity of the injection site. For these reasons,
we deemed it appropriate to inject a larger volume (3.0 µI).

A~

25-35 and

A~

35-25 (SACHEM, Torrance, CA) were supplied as a trifluoroacetic

acid (TFA) salt with the peptide content 84.4 and 82.15 ( ± 3%), respectively. According
to a representative at BACHEM there is no direct stoichiometric relationship between the
content of

A~

25-35 and TFA. In order to not underestimate the amount of TFA, we

assumed that it was 1 5. 6 % of the weight of the salt. Therefore, there are approximately 2
nmol of TFA for each 1 nmol of

A~

25-35. The peptide and its respective vehicle (VEH;

TFA, sodium salt; Sigma) were dissolved in Nanopure® H 2 0 (H 2 0) immediately before use
and stored at 4°C between injections. The reverse peptide was handled in the same
manner.

Animal Sacrifice and Tissue Preparation
Animals were anesthetized with sodium pentobarbital (100 mg/kg, i.p.) and perfused
transaortically at 8 or 32 days postoperatively with 250 ml of 0.1 M sodium/potassium
phosphate buffer (PB, pH 7.4), followed by 500 ml of 4% paraformaldehyde in PB at a rate
of 500 ml/h at room temperature. Immediately after beginning the perfusion, 1 .0 U/g
heparin (Upjohn, Kalamazoo, Ml) was administered transaortically. Following perfusion the
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brain was placed in the buffered fixative with 20% sucrose for 1.0 h. The brain was then
trimmed into a 6 mm block surrounding the injection site, and stored in a solution containing
20% sucrose, 0.1 % sodium azide and 0.01 % bacitracin in PB for 24 hat 4°C. The tissue
block was then transferred to a solution containing 20% glycerol and 2% dimethyl sulfoxide
dissolved in 0.1 M sodium phosphate buffer, and stored at 4°C until it was sectioned.
Serial coronal sections (40 µm) were cut and five series of sections at 0.2 mm intervals
were obtained for histological analysis using 1) cresyl violet, 2) tau-2, 3) Alz-50, and 4)
GFAP. The first series was immediately mounted on slides, dried, and stained with cresyl
violet. The other series were placed in an ethylene glycol cryoprotectant and stored at 20°C until used for immunohistochemistry.

Histology
1) Cresyl violet: The mounted sections (40 µm) from one series were defatted in
xylene and hydrated using ethyl alcohol and H 2 0. Staining was performed for 20 min in a
solution containing 200 ml of 0.2 M acetic acid, 133 ml 0.2 M sodium acetate and 67 ml of
0.1 % cresyl violet acetate. The sections then were dehydrated in an ethyl alcohol series
and cleared in xylene. The tissue was subsequently coverslipped using DePeX mounting
medium.
2) Tau-2: A series of 40 µm sections were removed from the cryoprotectant and
washed overnight in phosphate buffered saline (PBS; pH 7.4) at 4°C. Sections were
subsequently placed in 0.3% H 2 0 2 in Tris buffered saline (TBS; pH 7 .6) for 30 min, and
then washed 3 x 10 min in 0.3% Triton X-100 in TBS. The sections then were incubated in
primary antibody tau-2 (Sigma) at a 1: 500 dilution for 24 h at room temperature. The
antibody diluent contained 2.0% Triton X-100, 0.1 % sodium azide, 0.01 % bacitracin, 2%
bovine serum albumin, and 10% normal horse serum in TBS. Subsequently, the tissue was
washed 3 x 1 O min in 0.3% Triton X-100 in PBS, and then incubated for 1.0 h in
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biotinylated anti-mouse immunoglobulin (lg) G secondary antibody (Vectastain ABC Elite kit,
Vector Laboratories, Burlingame, CA) diluted 1 :2000 in 0.3% Triton X-100 in PBS.
Following two washes in 0.3% Triton X-100 in PBS for a total of 15 min, the tissue then
was incubated for 1 .0 h in avidin horseradish peroxidase (Vector) diluted 1 :2000 in 0.3%
Triton X-100 in PBS. The sections were washed in PBS for 1 .0 h, and sodium acetate
buffer (0.2 M, pH 6.0) for 15 min, and then reacted in 3,3'-diaminobenzidine
tetrahydrochloride (DAB) with nickel ammonium sulfate intensification (35 mg DAB, 2.5 g
nickel ammonium sulfate per 100 ml sodium acetate buffer with 0.3% H 2 0 2 added in 10 µI
increments). Tissue sections then were placed in sodium acetate buffer, transferred to cold
PBS and left at 4°C overnight. Subsequently, the tissue was mounted on slides, dried,
defatted and cover slipped. According to product specifications, the biotinylated anti-mouse
lgG (Vector) has 25% cross-reactivity with rat lgG. We were able to reduce this nonspecific staining in the omit sections by diluting this secondary antibody. lmmunolabelled
cells in the omit sections were subtracted accordingly to establish a baseline.
3) Alz-50: Performed as above, except that 10% normal goat serum was used in
the primary antibody diluent instead of normal horse serum. Alz-50 (courtesy of Dr. L. I.
Binder) was used at a 1 : 1 000 dilution, and the secondary antibody was a peroxidaseconjugated goat anti-mouse lgM (Boehringer Mannheim, Indianapolis, IN), diluted to 1 :200.
4) GFAP: Performed the same way as tau-2 staining, except that 10% normal goat
serum was used in the primary antibody diluent instead of normal horse serum. The GFAP
antibody (Dako, Denmark) was used at a 1 :500 dilution. The secondary antibody was a
goat anti-rabbit lgG (Vector) diluted 1: 1333.
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Experimental Design
Experiment 1: Effects of AP 25-35 at 8 days postoperatively.

n

Drug (dose), right amygdala

9

VEH ( 10.0 nmol TFA/3.0 µI H2 0)

2

9

AP 25-35 (5.0 nmol/3.0 µI H 2 0)

Methods:

Cresyl violet, tau-2, Alz-50 and GFAP staining.

Group#

Both cresyl violet and tau-2 staining were performed on series from all the rats.
Because of limited amounts of the Alz-50 antibody, we were not able to stain all series.
Alz-50 staining was performed on a series of sections from two AP 25-35 treated rats that
showed intense tau-2 IR, and on the same number of VEH treated rats. GFAP staining was
performed on a series from eight VEH treated rats and five AP 25-35 treated rats.

Experiment 2: Effects of AP 25-35 at 32 days postoperatively.
Group#

n

Drug (dose), right amygdala

3

VEH (10.0 nmol TFA/3.0 µI H20)

2

4

AP 25-35 (5.0 nmol/3.0 µI H20)

Methods:

Cresyl violet, tau-2, Alz-50 and GFAP staining.

Cresyl violet, tau-2 and GFAP staining were performed on a series of sections from
all the rats. Alz-50 staining was performed on a series from two of the VEH treated rats
and all of the AP 25-35 treated rats. The Alz-50 and GFAP staining were performed
simultaneously on sections from the rats sacrificed 8 days postoperatively.
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In a separate experiment, we injected the same dose of the reverse peptide

(A~

35-

25) into the rat amygdala and examined GFAP and tau-2 IR at 8 days and 32 days
postoperatively (n =2-3). The same VEH (n =2-3) was used for comparison.

Data Analysis
Tau-2 IR cells were counted from 12 coronal sections (40 µm) surrounding the
cannula track. The number of tau-2 IR cells in distinct brain areas in the VEH and

A~

25-35

treated animals were analyzed using at-test (SIGMASTAT, version 1.01; Jandel, San
Rafael, CA). Reactive astrocytosis in the ipsilateral hippocampus was rated on a scale of 02 +. An animal was considered positive if it exhibited

~

1 + staining. The GFAP staining

was analyzed using a one-tailed Fisher exact test (SIGMASTAT). The rating of the GFAP
sections was based on the complexity of astrocytic branching within the hippocampus
(0 =resting astrocytes, few processes; 1 + =reactive astrocytes, moderate branching;
2 + =reactive astrocytes, extensive branching).
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Results

Experiment 1: Effects of AB 25-35 at 8 Days Postoperatively.

Cresyl violet:
No difference was seen in cresyl violet stained sections between VEH and AP 25-35
treated rats except for proteinaceous deposits in the amygdala of AP 25-35 rats (Figure 3AB). These deposits were identical to the Congo red positive deposits that we have observed
following AP 25-35 injections into the ventral pallidum/substantia innominata (VP/SI) (314).
Proteinaceous deposits did not form at the site of injection in rats treated with the reverse
peptide. Sections from the latter group of rats did not appear to differ from the VEH treated
rats.

Figure 3. Cresyl violet staining at 8 days postinjection. Coronal sections through VEH (A)
and AP 25-35 (8) injection sites. The cannula track and the tip of the injection are seen in
the VEH treated rat (A; arrowheads). Note the proteinaceous deposit (arrows) within the
cavitation in B. No other histological differences were discerned between the VEH and AP
25-35 groups. Scale bar=0.5 mm.
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A~

25-35 significantly increased tau-2 IR in the neuronal perikarya and processes

ipsilaterally in the amygdala

[A~

25-35: (mean± SEM) 226 ± 95 IR cells; VEH: 10 ± 7,

p<0.001], cingulate cortex

[A~

25-35: 94±30; VEH: 0, p<0.011 and hippocampus

[A~

25-35: 251 ± 78; VEH: 5 ± 4, p < 0.001] (Figures 4-6). IR cells were also seen in other brain
areas such as the parietal and pyriform cortices, hypothalamus, thalamus, globus pallidus,
claustrum, substantia nigra, VP/St, and the entorhinal cortex. No contralateral staining was
observed except in the hypothalamus and occasionally in the cingulate cortex. Sections
from rats treated with the reverse peptide did not appear to differ from the VEH treated rats.

51

A

Figure 4. Tau-2 IR at 8 days postinjection. Coronal sections adjacent to VEH (A) and A~
25-35 (8, C) injection sites. C is a magnification of the area bracketed in 8. Virtually no
tau-2 IR is observed in the VEH treated rat (A). A~ 25-35 induces neuronal cell body and
processes tau-2 IR in the amygdala (8, C). Scale bar (A) =0.5 mm. Scale bar (C) =20 µm.
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A

Figure 5. Tau-2 IR at 8 days postinjection. Coronal sections adjacent to VEH (A) and AP
25-35 (B, C) injection sites. C is a magnification of the area bracketed in B. Virtually no
tau-2 IR is observed in the VEH treated rat (A). AP 25-35 induces neuronal cell body and
processes tau-2 IR in the hippocampus (B, C), and cortical areas (8). Scale bar (A) =0.5
mm. Scale bar (C) = 20 µm.
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Alz-50:
An increase in Alz-50 IR was observed in the amygdala of the

A~

25-35 treated

animals. Several beaded fibers and an occasional neuronal perikarya were visualized with
Alz-50 in the ipsilateral amygdala and to a lesser extent in the contralateral amygdala.
Interestingly, no Alz-50 IR was observed in the basolateral amygdala. Moderate staining of
similar morphology also was observed ipsilaterally in the VP/SI and there was faint staining
ipsilaterally in the hippocampus. In addition, hypothalamic cell bodies and fibers were
observed bilaterally in both VEH and

A~

25-35 treated rats. Hypothalamic IR in normal rats

has been observed by others (32).

Reactive astrocytosis was observed in the ipsilateral amygdala but there did not
appear to be differences between

A~

25-35 and VEH treated animals. However, reactive

astrocytosis was seen in the ipsilateral hippocampus of all the

A~

25-35 treated rats (5/5)

but only in 50% of the VEH treated rats (4/8; p = 0.105). No reactive astrocytosis was
observed in rats treated with the reverse peptide.

Experiment 2: Effects of AB 25-35 at 32 Days Postoperatively.

Cresyl violet:
Microscopic analysis of the ipsi- and contralateral amygdala appeared to reveal
neuronal shrinkage within the right amygdala (injected site) of

A~

25-35 treated rats when

compared to the left amygdala. This finding, however, requires confirmation by quantitative
analysis in a larger number of animals. Proteinaceous deposits were observed 32 days
postinjection in the right amygdala bf

A~

25-35 treated rats. However, proteinaceous
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deposits did not form at the site of injection in rats treated with the reverse peptide.
Sections from these rats did not differ from the VEH treated rats.

A~

25-35 significantly increased tau-2 IR ipsilaterally in the amygdala

721 ±194 IR cells; VEH: 48±24, p<0.05) and hippocampus

(A~

(A~

25-35:

25-35: 938±84; VEH:

310 ± 161, p < 0.05) in rats 32 days postoperatively (Figure 6). As at 8 days
postoperatively, IR cell bodies and processes were also seen in other brain areas such as the
parietal and pyriform cortices, hypothalamus, thalamus, globus pallidus, claustrum,
substantia nigra, VP/SI, and the entorhinal cortex. Contralateral staining was only observed
in the hypothalamus and occasionally in the cingulate cortex. The staining appeared to be
more intense than at 8 days postoperatively but a similar anatomical distribution was noted.
Sections from rats treated with the reverse peptide did not appear to differ from the VEH
treated rats.

Alz-50:
The pattern and morphology of Alz-50 staining was similar to that observed at 8
days postoperatively but the intensity in the
32 days postoperatively (Figure 7).

A~

25-35 treated rats appeared to be greater at
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Figure 6. Quantitation of tau-2 IR cells at 8 days and 32 days postinjection. Following
unilateral intra-amygdaloid injection, there was a significant increase in ipsilateral tau-2 IR
cells in the amygdala, cingulate cortex and hippocampus in A~ 25-35 treated rats 8 days
postoperatively (A), and in the amygdala and hippocampus 32 days postoperatively (B)
when compared to VEH treated rats. Each bar represents the mean+ SEM of tau-2 IR cells
from 12 sections (40 µm) surrounding the cannula track. (A) **p<0.01; ***p<0.001; (8)

*p<0.05.

56

A

B

Figure 7. Alz-50 IR at 32 days postinjection. Coronal sections through VEH (A) and
adjacent to AP 25-35 (8, C) injection sites. C is a magnification of the area bracketed in 8.
Virtually no staining is observed in the VEH treated rat (A), but collection of red blood cells
are seen at the tip of the injection site. Several beaded fibers and an occasional neuronal
perikarya are visualized with Alz-50 in the amygdala of the AP 25-35 treated rat (8, C).
Note the lack of staining in the basolateral amygdala. Scale bar (A) =0.5 mm. Scale bar
(C) =20 µm.
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At 32 days, no reactive astrocytosis was observed in the VEH treated animals.
Reactive astrocytosis in the

A~

25-35 treated rats was predominantly observed within the

right hemisphere. These histological changes were seen in areas such as the amygdala,
hypothalamus and cortical regions but were seen most consistently within the hippocampus.
Reactive astrocytosis was observed in the ipsilateral hippocampus (Figure 8) of all the

A~

25-35 treated rats (4/4) but not in the VEH treated rats (0/3; p =0.029). No evidence of
reactive astrocytosis was observed in rats treated with the reverse peptide.
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Figure 8. GFAP IR 32 days postinjection. Coronal sections adjacent to VEH (A) and A~ 2535 (8, C) injection sites. C is a magnification of the area bracketed in B. Virtually no GFAP
IR is observed in the VEH treated rat (A). In the A~ 25-35 treated rat a reactive astrocytosis
is predominantly observed in the ipsilateral hippocampus (8, C; p =0.015). Scale bar
(A) =0.5 mm. Scale bar (C) =20 µm.
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Discussion

We have demonstrated that a unilateral intra-amygdaloid injection of

A~

25-35 in the

rat induces the appearance of abnormal tau proteins both within the ipsilateral amygdala as
well as at distant sites as recognized by the tau-2 and Alz-50 antibodies. These cytoskeletal
changes appeared to be progressive and associated with reactive astrocytosis. Studies have
reported local effects immediately surrounding the injection site of

A~

injections into rat

cerebral cortex and hippocampus (91, 178, 180), but there are no reports on

A~

injections

into the rat amygdala, and their distal effects.
The tau-2 antibody recognizes tau proteins in both the phosphorylated and nonphosphorylated form. This antibody does not discriminate between normal tau and
hyperphosphorylated Alzheimer's tau in unfixed tissue, but recognizes only the Alzheimer's
tau in fixed tissue (259). The epitope that tau-2 recognizes has been localized to the alanine
95 through alanine 108 sequence, in particular, amino acid 101 (346). On immunoblots,
tau-2 has a higher affinity for bovine tau, that has serine in position 101, than human,
mouse or rat tau, that all have praline in position 101. It has been suggested that the tau
comprising paired helical filaments has a serine 101 peptide-like conformation similar to that
seen for bovine tau (346). Therefore, the increase in tau-2 IR suggests that

A~

25-35 may

be causing a conformational change in tau proteins. Tau-2 IR cells were seen consistently in
several brain areas ipsilateral to the injection site of

A~

25-35 treated rats at 8 and 32 days

postoperatively. The anatomical distribution of senile plaques and neurofibrillary tangles in
AD suggests that

A~

may act on nerve terminals to cause cytoskeletal alterations in axons,

which ultimately lead to tangle formation within the perikarya (265). Therefore, the
appearance of abnormal tau IR following intra-amygdaloid injections of

A~

25-35 can be

expected in brain regions that project to the amygdala (Figure 9). Our results support this
view. The hippocampus and cortical areas have prominent bidirectional connections with
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the amygdala but the corpus striatum is one of only a few brain regions that receives
amygdaloid fibers but does not project back to the amygdala (276). The observation of tau2 IR cells in the hippocampus and cortical areas and relative lack of reactive cells in the
neostriatum supports the hypothesis that

A~

25-35 acts on nerve terminals to induce the

appearance of abnormal tau proteins in brain regions that have efferent projections to the
amygdala. It is unlikely that these distant effects are due to diffusion of the peptide from
the site of injection into the ventricles, because

A~

deposits were not observed outside the

site of injection. In addition, induced tau IR and reactive astrocytosis were not observed in
the ependymal lining of the ventricles.
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Figure 9. Schematic diagram of the right hemisphere of a coronal section through the AP
25-35 injection site. AP 25-35 in its p-pleated sheet conformation (stippled area in the
amygdala) acts on nerve terminals to induce the appearance of abnormal tau proteins in
brain regions that have efferent projections to the amygdala. The cingulate cortex and the
hippocampus are examples of brain regions that have prominent efferent connections
(dashed lines) with the amygdala. Amygdaloid interneurons are also shown projecting
{dashed lines) towards the A~ 25-35 deposit. Tau-2 positive cell bodies are represented by
black stars within white boxes. Abbreviations: CING: cingulate cortex; HIP: hippocampus;
AMY: amygdala; Hb: habenula; f: fornix.
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The Alz-50 antibody in immunocytochemical studies stains AD brain tissue (55) but
its IR in normal brain tissue appears to depend on the method used (293). It demonstrates
early changes in AD by recognizing abnormally phosphorylated tau protein (337). The
location and nature of the epitope recognized by Alz-50 remains controversial. It has been
reported to recognize an acid phosphatase sensitive phosphorylated epitope of tau that is
localized within the 14-amino acid carboxy-terminal to the tubulin-binding domain of tau
(337). However, the epitope also has been mapped to the amino-terminal region of tau
proteins (105, 182). Although the epitope that Alz-50 recognizes may not be
phosphorylated, the overall peptide conformation recognized by the antibody may be
phosphorylation dependent. In the present study, the morphology and distribution of the
Alz-50 staining differed from that of tau-2. Beaded fibers, but only an occasional perikarya,
were visualized with Alz-50 whereas tau-2 IR was observed in cell bodies and processes.
Alz-50 staining was predominantly observed in the ipsilateral amygdala, to a lesser extent in
the contralateral amygdala, and ipsilaterally in the VP/SI and hippocampus. At present,
there is no obvious explanation for the lack of IR in the basolateral amygdala. The ipsi- and
contralateral amygdala are connected through the anterior commissure (276), which may
explain the IR observed in the contralateral amygdala. In addition, the IR in the ipsilateral
VP/SI and hippocampus can be explained by prominent anatomical connections between
these brain regions and the amygdala (276). We did not attempt to quantify the effects of
A~

25-35 on Alz-50 IR because of the morphology of staining. lmmunohistochemistry was

performed simultaneously on sections from rats sacrificed 8 and 32 days postoperatively.
As with tau-2, staining appeared to be substantially more intense at 32 days postoperatively
but the pattern was similar to that observed 8 days postoperatively. This supports the
observation that A~ 25-35 induced effects on the cytoskeleton gradually increase up to 32
days postoperatively. The

A~

25-35 induction in Alz-50 staining suggests that the peptide

alters the conformation of tau proteins possibly through an increase in tau phosphorylation.
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We have recently found (unpublished observation) that

A~

25-35 increases Alz-50 IR on

Western blots 8 days postoperatively.
There is no obvious explanation for the differences in distribution and morphology
between Alz-50 and tau-2 staining. These two antibodies recognize different conformation
A~

dependent epitopes on tau proteins.

25-35 may be inducing multiple conformational

changes in tau proteins, which are differently stained using the two antibodies. The nature
and extent of these conformational changes may be time dependent, brain region specific,
and differ within the neuronal structure.
It can be argued that the

A~

25-35 induction in tau-2 and Alz-50 IR does not arise

from conformational change but rather is due to increased synthesis of tau proteins. We
have performed Western blot analysis on the amygdala of rats sacrificed 8 days
postinjection using the same experimental protocol as in this study. By using the tau-1
antibody that reacts only with normal and unphosphorylated tau (16), no differences were
observed in the molecular weights of tau-1 IR bands or their density when

A~

25-35 treated

rats were compared to VEH treated rats (unpublished observation). This finding suggests
A~

that the

25-35 induction in abnormal tau IR is not the result of an increased synthesis of

tau proteins.
The effects of
calcium.

A~

A~

on tau IR may be mediated through an increase in intracellular

has been shown to increase intracellular calcium (7,218), and calcium influx in

cultured rat hippocampal neurons caused by glutamate induces tau IR as recognized by the
antibodies Alz-50 and 5E2 (216). Protein kinases are generally activated by increases in
intracellular calcium and several of those have been shown to phosphorylate different sites
on tau proteins (238). Therefore,

A~

may increase the phosphorylation of tau proteins

through an activation of kinases mediated by an increase in intracellular calcium. The
activities of some phosphatases that may dephosphorylate tau proteins have been shown to

64
be decreased in AD (111,311 ). Therefore, A~ 25-35 may also be decreasing the
dephosphorylation of tau proteins through an inhibition of phosphatases.
The proteinaceous deposits observed at the site of injection, both at 8 and 32 days
postinjection, were identical to those we have observed following injection of

A~

25-35 into

the VP/SI (314). Those deposits were Congo red positive with birefringence under polarized
light, suggesting that they were most likely composed of fibrillar
with the peptide in its

~-pleated

A~

because the dye reacts

sheet conformation. Therefore, these findings further

support the notion that A~ 25-35 is not readily degraded in vivo, and suggest that its toxic
effects may gradually increase as long as the peptide is present in its toxic conformation

(~

pleated sheets).
GFAP immunohistochemistry was performed in order to determine 1) if A~ 25-35
increases reactive astrocytosis, like that seen surrounding senile plaques in AD; and, 2) if
there is a correlation between the location and severity of abnormal tau and GFAP IR.
Following stab wounds of the rodent cerebrum reactive gliosis reaches maximum intensity
3-7 days postoperatively (253). The contra lateral hemisphere is rarely affected and the glial
reaction is transient in nature and declines to nearly normal appearance by 3 weeks.
Therefore, the non-specific damage caused by the cannula placement may explain the similar
amygdaloid GFAP IR in

A~

25-35 and VEH treated rats at 8 days postoperatively. This

injury related effect may also explain the reactive gliosis in the ipsilateral hippocampus of
some of the VEH treated rats and thereby the lack of a significant effect of

A~

25-35 at 8

days postoperatively (p = 0.105). Microscopic analysis of cresyl violet stained sections did
not reveal any hippocampal neuronal loss. However, numerous tau-2 IR cells were observed
in the ipsilateral hippocampus at this timepoint, suggesting an association between neuronal
cytoskeletal changes and reactive astrocytosis. The transient nature of the glial reaction
caused by the cannula placement is supported by the lack of reactive astrocytosis in the
VEH treated rats 32 days postoperatively. Reactive astrocytosis was consistently observed
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in the ipsilateral hippocampus of the

A~

25-35 treated rats at this timepoint (p = 0.029).

These observations suggest a long lasting effect of A~ 25-35 on astrocytic reactivity in a
brain region that has prominent efferent connections with the amygdala.
In a separate experiment, we injected the same dose of the reverse peptide

(A~

35-

25) into the rat amygdala and performed cresyl violet, tau-2 and GFAP staining at 8 and 32
days postoperatively.

No difference was seen between rats treated with VEH and the

reverse peptide. It did not form proteinaceous deposits at the site of injection and did not
induce significant tau-2 IR or reactive astrocytosis. Therefore, the histopathological effects
of A~ 25-35 are specifically caused by that particular amino acid sequence. The effects of
A~

25-35 in present study, furthermore, are not caused by its greater acidity (pH 3.5-3.9)

than the VEH solution (pH 5.9-6.0), as the acidity (pH 3.6) of the same dose of the reverse
peptide, was similar to that of

A~

25-35.

Animal models can be evaluated in terms of construct validity, face validity and
predictive validity. We believe that this model has construct validity because we are
injecting a fragment of a peptide, that may play a prominent role in the etiology of AD, into
a brain region that is affected early in the disease. The most appropriate face validity of an
animal model of AD would be the demonstration of senile plaques associated with reactive
astrocytes, neurofibrillary tangles, and neuronal cell loss in the same brain regions as
observed in AD. It is unlikely, however, that this effect can be obtained using a single
injection of

A~

into rat brain, but this approach may demonstrate the early histopathological

changes in AD. In our opinion, the present rat model has a relatively high face validity
because of the induction of abnormal tau proteins and reactive astrocytes in brain regions
where the primary and early histopathological changes in AD are observed. Currently, no
definitive transgenic animal models are available that resemble all aspects of AD, although
plaque-like

A~

deposits have been observed (98). The predictive validity of the present rat
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model, as well as future transgenic models, will ultimately determine their usefulness in
screening potential drugs for therapy.
In conclusion, these data suggest that injection of Af3 25-35 into the right amygdala
of young rats induces progressive transsynaptic cytoskeletal and astrogliotic reactions that
gradually spread from the amygdala to brain regions that have prominent efferent
connections with that area. These findings also suggest a direct association between
plaque and tangle formation in AD, and support the use of this rat model to screen drugs
that may attenuate or enhance the initial pathological events associated with AD.

CHAPTER IV

LATERALITY IN THE HISTOLOGICAL EFFECTS OF INJECTIONS OF AMYLOID-~ 25-35 INTO
THE AMYGDALA OF YOUNG MALE FISCHER RATS

Abstract

We have observed that single

amyloid-~

25-35

(A~)

injections (5.0 nmol) into the

right amygdala of rats produce progressive cytoskeletal and astrogliotic reactions not only
within the amygdala, but also in distal brain regions that project to the amygdala. To
determine if these effects are potentiated by bilateral injections, we injected

A~

(5.0 nmol)

into the left and right amygdala of young male Fischer rats. Animals were sacrificed at 32
days postoperatively. Bilateral infusions of

A~

induced significant neuronal shrinkage, tau-2

neuronal staining and reactive astrocytosis within the right amygdala and/or hippocampus,
compared to vehicle treated rats. Surprisingly, the same brain regions within the left
hemisphere were significantly less affected even though no differences were observed
between the left and right amygdala in the size of Congo red positive
Unilateral injections of

A~

A~

deposits.

into the left amygdala led to significant histological changes in the

right amygdala and hippocampus but not in the same brain regions within the left
hemisphere. These results suggest a laterality in the histopathological effects of
Fischer rats. Identification of the cause for the lateralized effect of

A~

A~

in male

may prove valuable

for understanding the etiology of Alzheimer's disease and provide possible therapeutic
strategies designed to slow the progression of the disease.
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Introduction

The histopathological characteristics of Alzheimer's disease (AD) include senile
plaques, reactive astrocytes, neurofibrillary tangles, and neuronal cell loss in several brain
regions. Senile plaques consist predominantly of

amyloid-~ (A~)

which is derived from a large membrane spanning protein, the

1-42 ( 103,214,233,285),

amyloid-~

precursor protein

(APP) ( 1 66). Mutations in APP in some forms of familial AD are associated with an elevated
production of

A~

(33,39,331 ). APP is overexpressed in Down's syndrome (248,291 ), and

individuals with this disease invariably develop the neuropathological hallmarks of AD
(23, 1 87). The proposed role for
neurotoxicity of

A~

A~

in the pathogenesis of AD is further supported by the

(369,370), that includes amino acids 25-35 of the peptide (370).

A~

A~

into

toxicity depends on its aggregation state (269,273), and requires the assembly of
amyloid fibrils composed of a

~-pleated

sheet structure (203). Other amyloidogenic peptides

also are toxic to neurons in vitro, including amylin, serum amyloid P component, and a
peptide derived from the prion protein (87,202,222,338). These findings suggest that the
structure of the fibril, rather than its amino acid sequence, is responsible for its toxicity.
The discovery of the association of AD with inherited APP mutations led to the development
of transgenic mouse models containing these mutations. Recently, two mouse models have
been described that contain age dependent congophilic

A~

plaques similar to those observed

in AD (98, 145), and in one of these models these changes are associated with behavioral
impairments (145).
The main component of neurofibrillary tangles is paired helical filaments ( 168,335),
which consist largely of the microtubule associated protein tau in an abnormal state of
phosphorylation ( 171, 182,355,356). Only recently have a few studies demonstrated a
direct association between plaque and tangle formation using in vitro and in vivo models. In
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vitro studies have demonstrated that AP increases tau protein kinase I (TPK I) activity (332),
induces tau immunoreactivity (IR) (26,207), and that the neuronal death caused by AP can
be prevented with TPK I antisense oligonucleotides (332). In vivo studies have reported
that AP can induce tau IR in the vicinity of the injection site (91, 178, 180,317), as well as at
distal sites (317). Also, one report indicates that injection of hyperphosphorylated tau into
rat brain induces AP IR (312).
In the AD brain, reactive astrocytes are found in high abundance surrounding senile
plaques (70). Glial fibrillary acidic protein (GFAP) (77) is a component of the glial
intermediate filaments that form part of the cytoskeleton, and is found predominantly in
astrocytes. GFAP levels in AD brains are increased 8 to 16 fold compared to control brains
(21,60). Recent in vitro (34,141,271) and in vivo (317) findings suggest that AP induces
reactive astrocytosis.
The major pathological changes in AD are found in regions of the medial temporal
lobe, including the amygdala (265). Previously, we observed that single AP 25-35 injections
(5.0 nmol) into the right amygdala of rats produce progressive (8 vs. 32 days) cytoskeletal
and astrogliotic reactions not only within the amygdala, but also in distal brain regions that
project to the amygdala (317). To determine if these effects are potentiated by bilateral
injections of Ap, we injected AP 25-35 (5.0 nmol) into the left and right amygdala of young
male Fischer-344 rats. The present study suggests that there is a laterality in the
histological effects of AP.
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Materials and Methods

Animals
Male Fischer-344 rats were obtained from the NIA colony at Harlan Sprague-Dawley
(Indianapolis, IN). At the time of arrival, the rats weighed 250-300 g and were 3-4 months
of age. The animals were housed individually, maintained on a 12 h light-dark cycle (lights
on at 07:00 h) in a AAALAC approved facilities, had access to food and water ad libitum,
and were habituated to their new environment for 2-3 weeks prior to surgery.

A~

25-35 (BACHEM, Torrance, CA) was supplied as a trifluoroacetic acid (TFA) salt.

At the time of surgery, information was not available from the supplier regarding the amount
of TFA per mg of the salt of the peptide. According to the supplier, there is not a direct
stoichiometric relationship between the content of

A~

25-35 and TFA, in other words it is

not known how many mol of TFA there are in each mol of the TFA salt of

A~

25-35. The

peptide content was 77% ( ± 3%) with the remaining 23% consisting of TFA and H 2 0, and
the purity of the peptide was
of

A~

> 98%.

We assumed that there are 2 nmol of TFA per 1 nmol

25-35, that is TFA content of 16.7% per mg of the salt. Recent information from the

supplier indicates that the TFA content is 9. 7 % . The peptide and its respective vehicle
(VEH; TFA, sodium salt; Sigma) were dissolved in Nanopure® water (H 2 0) immediately
before use and stored at 4 °C between injections.

Surgery
Surgery was performed as described previously (317). Briefly, the animals received
bilateral injections of 5.0 nmol/3.0 µI (n = 20), or its respective VEH (n = 13), into the
amygdala. The rats were either injected first into the right amygdala and subsequently into
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the left amygdala
left amygdala

(A~

(A~

rats= 1O; VEH rats= 7), or injected simultaneously into the right and

rats= 10; VEH rats= 6). In addition, a few rats

received unilateral injections of

A~

(A~

rats= 4; VEH rats= 2)

25-35 (5.0 nmol/3.0 µI) into the left amygdala. A Kopf

stereotaxic instrument was used with the incisor bar set at 3.3 mm below the interaural line.
Injection coordinates measured from the bregma and the surface of the skull (AP - 3.0, ML
± 4.6, DV - 8.8) were empirically determined based on the atlas of Paxinos and Watson

(261 ).

Animal Sacrifice, Tissue Preparation and Histology
The animals were anesthetized with sodium pentobarbital ( 100 mg/kg,
intraperitoneally) and perfused transaortically 32 days postoperatively, as previously
described (317). Serial coronal sections (40 µm) were cut with five series of sections at 0.2
mm intervals saved for histological analysis of 1) cresyl violet, 2) tau-2, 3) GFAP, and 4)
Congo red staining. lmmunohistochemistry was performed as previously described (317).
Briefly, sections (40 µm) were incubated in tau-2 (Sigma, St. Louis, MO) primary antibody at
a 1 :500 dilution for 24 h at room temperature. An anti-mouse immunoglobulin (lg) G
secondary antibody (Vectastain ABC Elite kit, Vector Laboratories, Burlingame, CA) was
used at a 1 :2000 dilution. GFAP staining was performed the same way as the tau-2
staining. The GFAP antibody (Dako, Denmark) was used at a 1 :500 dilution. The
secondary antibody was a goat anti-rabbit lgG (Vector) diluted 1: 1333. Omit sections for
tau-2 and GFAP were obtained by omitting the primary antibody. According to product
specifications, the biotinylated anti-mouse lgG (Vector) has 25% cross-reactivity with rat
lgG. We were able to reduce the intensity of this non-specific staining by diluting the
secondary antibody. The staining intensity was always substantially less in the omit
sections than in sections treated with the primary tau-2 antibody. lmmunolabelled neurons
in the omit sections from the same animal were subtracted accordingly to establish a
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baseline. In the VEH treated animals, the number of cells in the omit sections, regardless of
the intensity of staining, was 43% of the total cell number in the primary antibody sections.
In the

A~

treated rats, the number of cells in the omit sections was 23% of the total cell

number in the primary antibody sections. This percentage (23%) is in accordance with the
25% cross-reactivity of the secondary antibody. There was relatively more non-specific
staining in the VEH treated rats (i.e. 43% of total staining) than might be expected but this
may be due to the fact that few VEH treated animals had tau-2 positive cells (31 %), and
there was a low number of positive cells in those animals.

Data Analysis
The

A~

deposits, neuronal shrinkage and tau-2 staining were analyzed quantitatively.

The size of the deposits and the neuronal perikarya were measured, and tau-2 IR neurons
were counted. Reactive astrocytosis was analyzed semi-quantitatively by using a rating
scale.
An image analysis system (NIH Image 1.49) was used to determine the size of the
A~

deposits and neuronal shrinkage within the left and right amygdala. The area of the

A~

deposits was measured at 0.2 mm intervals. These data were analyzed using at-test
(SIGMASTAT, version 1.01; Jandel, San Rafael, CA) for comparison of the deposit area in
the left vs. right amygdala. The basolateral nucleus within the amygdala can be divided into
parvicellular and magnocellular subnuclei based on the cytoarchitecture of the neurons. The
cells within these subnuclei have a relatively uniform appearance and their boundaries are
easily identified. The magnocellular division is located mainly rostral and medial to the
parvicellular division. The area of 10 of the largest magnocellular cells (X400 magnification)
within the left and right basolateral amygdala was measured in one cresyl violet stained
section per animal slightly rostral to the injection site, and we carefully chose sections at a
similar coronal level. The average area of these 10 cells was calculated and the data were
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analyzed by a t-test for the unilateral

A~

injections, and a two-way analysis of variance

(ANOVA; SIGMASTAT) for the bilateral injections, followed by a Newman-Keuls' multiple
range test for post hoc comparisons. Tau-2 IR neurons were counted in the left and right
amygdala in six sections surrounding the injection site, and in six hippocampal sections
including and caudal to the injection site. Tau-2 IR neurons were also counted in omit
sections and subtracted accordingly. These data were analyzed using a two-way ANOVA
for the amygdala and hippocampus separately, followed by a Newman-Keuls' multiple range
test for post hoc comparisons. When the tau-2 data failed a normality test, it was analyzed
by a two-way ANOV A on ranks. The correlation between the number of tau-2 positive
neurons and neuronal cell size within the left and right amygdala, as well as the correlation
between the number of tau-2 positive neurons within the amygdala and hippocampus, was
analyzed using the Pearson product-moment correlation (SIGMASTAT).

Reactive

astrocytosis in the left and right hippocampus was rated on a scale of 0-2 + . An animal
was considered positive if it exhibited

~

1 + staining. These data were analyzed using a

Fisher exact test, one-tail (SIGMASTAT). The rating of the GFAP sections was based on the
complexity of astrocytic branching within the hippocampus (0 =resting astrocytes, few
processes; 1 + = reactive astrocytes, moderate branching; 2 + = reactive astrocytes,
extensive branching). The observers did not know which rat numbers corresponded to
which treatment. However, the

A~

treated animals were easily identifiable because of the

proteinaceous deposits within the amygdala.
No statistical difference was discerned, in any of the parameters analyzed, between
rats injected first into the right amygdala and subsequently into the left amygdala, and
animals injected simultaneously into the left and right amygdala, so they were combined in
the subsequent analyses.
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Results

Bilateral Injections into the Amygdala

AB Deposits
Proteinaceous deposits were observed bilaterally in the amygdala of the AP 25-35
treated rats (Figures 1 OA, B; 11; 14A). The location of the deposits did not vary between
the left and right amygdala. The deposits were found consistently medial to the basolateral
nucleus at the injection site, and their size appeared to be less than that of the basolateral
nucleus. These deposits were Congo red positive (apple-green birefringence under polarized
light; Figure 11 ), similar to those we observed following AP 25-35 injections into the ventral
pallidum/substantia innominata (VP/SI) (314). Of the 20 rats injected bilaterally with AP 2535, deposits were observed bilaterally in 18 rats, and unilaterally in 2 rats. Analysis of the
area of these deposits within the left vs. the right amygdala revealed no significant
differences (Figure 14A).

Cresyl Violet
Analysis of the areas of 10 of the largest magnocellular cells within the left and right
basolateral amygdala revealed a treatment effect of AP 25-35 [F( 1, 62) = 18.649,
p<0.001]. Laterality was also observed [F(1,62)=31.981, p<0.001], and there was a
significant treatment x laterality interaction [F(1,62) = 9.469, p = 0.003]. Post hoc analysis
revealed that bilateral intra-amygdaloid injections of AP 25-35 caused neuronal shrinkage
2

within the right amygdala [cell area= 1433 ± 82 µm (SEM); p < 0.01], compared to VEH
injections [cell area= 2040 ± 84µm 2 ; Figure 148]. The left amygdala in the AP treated rats
[cell area=2150±71µm

2

]

was significantly less affected than the right amygdala (p<0.01;

Figure 148). There was no significant difference between the cell area of the left [cell

area= 2252 ± 80µm

2

]

and the right [cell area= 2040 ± 84µm

2

]
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amygdala in the VEH treated

rats. All nuclei within the right amygdala appeared to be equally affected but the shrinkage
was most obvious in the large neurons within the basolateral amygdala (Figure 1 OA, 8).
The neuronal atrophy appeared to extend into other brain regions within the right
hemisphere, such as cortical areas. Cell bodies within the hippocampus overlapped and,
therefore, analysis of cell shrinkage was not performed in that brain region.

Figure 10. Neuronal shrinkage within the right amygdala. Cresyl violet stained coronal
section (X63) through the left (A) and right (8) amygdala in a bilaterally injected A~ rat. A~
deposits are seen bilaterally adjacent to the basolateral nuclei. Note the neuronal shrinkage
within the right (8) but not the left basolateral nucleus (A). In this animal, the average area
of 1 0 of the largest magnocellular cells was 1 986 ± 1 87 µm 2 (SD) in the left nucleus, and
2
1016 ± 178 µm in the right nucleus.
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Figure 11. Congo red positive AJ3 deposit. Congo red stained coronal section (X63)
through the injection site within the left amygdala in a bilaterally injected AJ3 rat. Note the
birefringence of the AJ3 deposit under polarized light that indicates a (3-pleated sheet
structure.
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There was a treatment effect of

A~

25-35 in the induction of specific neuronal tau-2

staining within the amygdala [F(1,60)=22.150, p<0.001) and the hippocampus
[F(1,60)=34.513, p<0.001) (Figure 14C, D). Laterality was observed in the amygdala
[F(1,60) = 31. 782, p < 0.0011 and the hippocampus [F(1,60) = 9.266, p =0.003] (Figure 12;
14C, D). There was also a significant treatment x laterality interaction within the amygdala
[F(1,60) = 8.198, p =0.006], but not within the hippocampus [F(1,60) = 3.096, p =0.084).

Post hoc analysis for the treatment effect revealed a significant increase in the number of
tau-2 IR neurons in the

A~

treated rats within the right amygdala (p<0.01) and the right

hippocampus (p < 0.01 ), compared to the same brain regions in the VEH treated rats.
Interestingly, there was also a significant increase in the number of tau-2 positive neurons
within the left hippocampus in the

A~

treated rats (p < 0.05), compared to VEH treated rats.

Post hoc analysis for the laterality effect revealed a significant increase in the number of tau2 IR neurons in the right amygdala (p < 0. 01 ) and the right hippocampus (p < 0. 01 ),
compared to the same brain regions within the left hemisphere in the

A~

treated rats. There

also appeared to be an increase in tau-2 IR neurons in other brain areas, predominantly on
the right side, including the cingulate, parietal and pyriform cortices, hypothalamus,
thalamus, globus pallidus, claustrum, substantia nigra, VP/SI, and the entorhinal cortex (data
not shown). Within individual animals, there was a significant positive correlation between
the number of tau-2 IR neurons within the amygdala and hippocampus (r=0.833,
p<0.001 ). There was also a significant negative correlation between the number of tau-2
positive cells and cell size within the left and right amygdala (r=-0.67, p<0.001 ).
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Figure 12. Laterality in tau-2 IR. Tau-2 stained coronal section through the left (A) and
right (C) hippocampus (X63), and the left (8) and right (D) amygdala (X63) in a bilaterally
injected Aj3 rat. E (X250) is a magnification of the area bracketed in C. No tau-2 IR is
observed within the left hippocampus (A) or the left amygdala (8) although an Aj3 deposit is
visible (arrows). Note the neuronal tau-2 IR within the right hippocampus (C, E) and the
right amygdala (D) in this same animal.
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Reactive astrocytosis was observed predominantly within the right hippocampus in
AP treated rats (p<0.001), compared to VEH treated rats (Figures 13C-F; 14E). The left
hippocampus was significantly less affected (p < 0.001; Figure 14E). These histological
changes were seen most consistently within the right hippocampus although other areas of
the right hemisphere appeared to be also affected. However, it should be noted that the left
hippocampus had occasionally moderate reactive astrocytosis (Figure 1 3A, 8) in rats with
the most severe gliosis in the right hippocampus (Figure 13C, D). Reactive astrocytes
appeared to be also associated with the AP deposits, and with the cannula track in both
treatment groups.

Figure 13. Laterality in GFAP staining. GFAP stained coronal section through the left (A, 8)
and right (C, D) hippocampus in a bilaterally injected AP rat, and through the right (E, F)
hippocampus in a bilaterally treated VEH rat. Reactive astrocytosis is moderate in the left
hippocampus (A, 8), whereas prominent reactive astrocytosis is observed in the right
hippocampus (C, D). No effect is observed in the VEH treated rat (E, F). 8, D and F (X250)
are magnifications of the areas bracketed in A, C and E (X63), respectively. The AP infused
rat represents a rating of 1 + in the left hippocampus and a rating of 2 + in the right
hippocampus. The VEH injected rat represents a rating of 0 in the right hippocampus.
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Figure 14. A~ deposits, neuronal shrinkage, tau-2 and GFAP staining. A quantitative
analysis of the size of the AP deposits (A) and neuronal shrinkage (B) within the right
amygdala vs. the left amygdala. Each bar represents the mean+ SEM of n = 13-20 rats. No
significant difference was seen between the left and right amygdala in the size of the AP
deposits. A quantitative analysis of neuronal tau-2 IR within the left and right amygdala and
hippocampus is shown in C and D, respectively. Each bar represents the mean+ SEM of
n = 13-19 rats. A semi-quantitative analysis of reactive astrocytosis within the left and right
hippocampus is illustrated in E. The data are presented as the percentage of positive rats
(rating of 21 +) of total rats (n = 13-20) analyzed.
*** p<0.001 [Ap RHIP vs. VEH RHIP]; ### p<0.001 [Ap RHIP vs. AP LHIP]; ** p<0.01
[Ap RAMY or RHIP vs. VEH RAMY or RHIPl; ## p<0.01 [Ap RAMY or RHIP vs. AP LAMY
or LHIP]; x p < 0.05 [Ap LHIP vs. VEH LHIP]. Abbreviations: LHIP: left hippocampus; RHIP:
right hippocampus; LAMY: left amygdala; RAMY: right amygdala; LDEP: AP deposits, left
amygdala; RDEP: AP deposits, right amygdala.
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Unilateral Injections into the Left Amygdala

Analysis of the areas of 1 0 of the largest magnocellular cells within the left and right
basolateral amygdala in the AP treated rats revealed a significant difference [t = 3.4 72,
2

df = 6, p = 0.013] between the left [cell area= 2309 ± 92 µm (SEM)l and right amygdala [cell
area= 1535±203 µm

2

].

There was a treatment effect of AP 25-35 in the induction of

specific neuronal tau-2 staining within the amygdala [F(1,8) = 6.122, p = 0.038], but not
within the hippocampus. Laterality in tau-2 neuronal staining was also observed in the
amygdala [F(1,8) = 55.102, p < 0.001 l (Figure 15A, 8), but not in the hippocampus. Post
hoc analysis revealed a significant increase in the number of tau-2 IR neurons within the

right amygdala in the AP treated rats (267 ± 95) compared to the right amygdala in the VEH
treated rats (78± 10, p<0.05). There was also a significant increase in the number of tau-2
IR neurons in the right amygdala vs. the left amygdala in the AP (right= 267 ± 95;
left= 1 ± 1, p < 0.01) and the VEH treated rats (right= 78 ± 10; left= 0, p < 0.05),
respectively. In all 4 rats injected with AP 25-35 into the left amygdala, reactive
astrocytosis was observed in the right hippocampus but not the left hippocampus
(p = 0.014). The regional distribution of these histological changes appeared similar to that
observed following unilateral injections into the right amygdala (317), as well as following
bilateral infusions.

Figure 15. Tau-2 IR within the right amygdala following injection of AP 25-35 into the left
amygdala. Tau-2 stained coronal section (X63) through the left (A) and right (8) amygdala
in an AP treated rat injected only into the left amygdala. No tau-2 IR is observed in the left
amygdala (A), although an AP deposit is visible. Note the induction of neuronal tau-2 IR
within the right amygdala (8) in this same animal.
·
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Discussion

We have confirmed our previous finding (317) that injection of

A~

25-35 into the

right amygdala induces neuronal cytoskeletal changes and reactive astrocytosis within the
amygdala, as well as at distal sites within the right hemisphere. Surprisingly, following
bilateral injections, these changes were predominantly observed within the right amygdala
and hippocampus whereas the same brain regions in the left hemisphere were significantly
less affected. To our knowledge, this is the first report demonstrating a laterality in the
histological effects of

A~

injected intracerebrally.

The reproducibility of

A~

toxicity in vivo has been inconsistent

(42,91,99,101,102,178,180,314,317,320,354). This may be due to variations in: 1) the
conformational state (25,269,273), dose, and sequence of

A~;

2) method of administration;

3) pathological endpoints measured; 4) what brain region and/or hemisphere is injected
(present study); 5) postoperative interval; and, 6) species and/or strain used.
The anatomical distribution of senile plaques and neurofibrillary tangles in AD
suggests that

A~

may act on nerve terminals to cause cytoskeletal alterations in axons,

which ultimately lead to tangle formation within the perikarya (265). This notion is
supported by the observation that the APP is predominantly located in the synaptic zone of
neurons (301 ). Therefore, deposition of

A~

fibrils and their initial toxic effects would

primarily occur near their site of generation, namely at the nerve terminals. These effects
then would gradually spread to distal brain regions that send axons to the area of initial
deposition. Our findings support this view.
As discussed previously (317), the increase in tau-2 IR suggests that

A~

25-35 is

causing a conformational change in tau proteins. These cytoskeletal changes are associated
with neuronal shrinkage and reactive astrocytosis, and this may simulate the initial
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histopathological changes that occur in AD. Reactive astrocytosis appears to be a more
sensitive marker of toxicity than tau-2 IR and neuronal shrinkage, but the AP 25-35 effects
are comparable using these three different markers (Figure 14). There appeared to be a
good correlation within individual rats between the extent and regional distribution of
reactive astrocytosis, cytoskeletal changes, and neuronal shrinkage.
Congo red positive (apple-green birefringence under polarized light) AP deposits were
consistently observed at the site of injection. This indicates that the deposits were
composed of a p-pleated sheet structure, the prominent conformation of AP in senile
plaques. It can be argued that although the aggregation state of the peptide can be revealed
by Congo red, AP immunostaining is necessary to prove the identity of the peptide.
Unfortunately, there is no antibody commercially available that specifically detects AP 2535. However, the characteristic apple-green birefringence was not observed in VEH treated
rats but always in AP treated rats with proteinaceous deposits. The consistency and
persistence of AP deposits within the brain likely depends on several factors, such as the
method of administration, solvent, dose, volume, sequence of Ap, and brain region injected.
The presence of heparan sulfate proteoglycans has been shown to be important for
consistent in vivo deposition of AP 1-40, and persistence of fibrillar AP in the rat
hippocampus (321). Furthermore, AP 25-35 deposits within the rat nucleus basal is are
degraded more rapidly than AP 1-40 deposits ( 102). AP in vitro develops protease
resistance to degradation when polymerized into fibrils (252), and acetylcholinesterase
(AChE) has been shown to promote the formation of and/or stabilize AP fibrils (150). Since
the basolateral amygdala, adjacent to the injection site, contains very high levels of AChE
(261 ), this proposed role of AChE may explain the consistency and persistence of the AP
fibrils in the present study. Importantly, no hemispheric differences were observed in the
size of the AP deposits (Figure 14A), indicating that the laterality in the histological effects
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of AP 25-35 can not be explained by variations in fibril formation and/or degradation
between the left and right amygdala.
Previously, we have injected the same dose of the reverse peptide (AP 35-25) into
the right amygdala and performed cresyl violet, tau-2 and GFAP staining at 8 and 32 days
postoperatively (317).

No difference was seen between rats treated with VEH and the

reverse peptide. AP 35-25 did not form proteinaceous deposits at the site of injection and
did not induce significant tau-2 IR or reactive astrocytosis. Therefore, the histopathological
effects of AP 25-35 are specifically caused by that particular amino acid sequence.
We tried to exclude experimental artifacts by measuring three different cellular
variables. Staining with antibodies for abnormal conformation of tau, for GFAP, and cresyl
violet staining all suggested a laterality in the effects of AP 25-35. Also, because both the
left and right amygdala were treated in exactly the same manner, each side served as an
internal control for the other side. In addition, unilateral injections into the left amygdala
alone caused histopathology only within the right amygdala and hippocampus. This
observation indicates that surgical damage to the right hemisphere is not the principal
source for the histopathological changes. The observed laterality effect, therefore, is unlikely
to be due to an experimental artifact. We are currently investigating injections into other
areas of brain, as well as different strains of rats to determine if the laterality effect of AP
25-35 is brain region and/or strain specific.
At present, there is no obvious explanation for the laterality effects of AP 25-35. In
four rats, unilateral injections into the left amygdala caused an induction in tau-2 IR within
the right amygdala but not the left amygdala (p<0.01; Figure 15A, 8). Also, reactive
astrocytosis was observed within the right hippocampus in all 4 rats but not the left
hippocampus (p=0.014). The regional distribution of these histological changes within the
right hemisphere appeared to be similar to that observed following bilateral infusions, as well
as following unilateral injections into the right amygdala (317). Since the left and right

amygdala are connected through the anterior commissure (276),

A~
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25-35 may be affecting

the efferent terminals of neurons whose cell bodies originate within the right amygdala, and
the laterality may be explained by hemispheric differences in secondary responses such as
immune functions (249).
Some investigators have demonstrated lateralization in the involvement of the rat
amygdala in learning and memory (15,45-47), and lesions of various brain regions in rats
(36,61, 121, 184,262,281,329,342) and mice (10) have asymmetrical effects. Ligation of
the right middle cerebral artery has been shown to lead to hyperactivity and reductions in
norepinephrine and dopamine, whereas ligation of the left middle cerebral artery has no
behavioral or neurochemical effects (281). Also, occlusion of the left or right middle
cerebral artery has different effects on mean arterial pressure, renal sympathetic nerve
discharge, and plasma norepinephrine levels ( 1 21). Suction lesions of the right frontal
cerebral cortex induce hyperactivity (61,262), that is accompanied by a bilateral decrease in
norepinephrine concentrations (262). However, identical lesions of the left cortex do not
produce hyperactivity (61,262) or a decrease in norepinephrine concentrations (262). Left
cortical ablations affect mainly the activity of serotonergic inputs to the right neocortex,
whereas ablations of the right cortex influence the activity of the catecholaminergic inputs
to the left cortex ( 1 0). Ablations of the prefrontal or parietal cortices lead to lateralized
brain immunomodulation (342). Kainic acid injections into the right frontal cortex produce a
significantly greater hyperactivity than identical injections into the left hemisphere ( 1 84).
Striatal lesions with 6-hydroxydopamine lead to greater dopamine depletion in right-lesioned
rats than in left-lesioned rats (329). Also, left and right 6-hydroxydopamine lesions of the
medial prefrontal cortex differentially alter subcortical dopamine utilization and the behavioral
response to stress (36).
Asymmetries have been observed in the histopathological hallmarks (52,235), and in
the reductions in choline acetyltransferase activity (235,287) in individual cases of AD, but
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preferential involvement of either hemisphere has not been demonstrated in groups of AD
patients. Interestingly, asymmetry in the density of senile plaques diminishes with
increasing neuropathological severity (235), suggesting that laterality may be more
prominent in the initial stages of the disease. In AD, there is an extensive neuronal loss and
shrinkage in all subdivisions of the amygdala (340), but no left-right hemispheric differences
were detected in total neuron numbers in a study of 9 AD cases (340). However,
hemispheric laterality in cerebral metabolism and perfusion in AD has been demonstrated in
several studies. In most of these reports, there is no left-right preference in this asymmetry
(37,68,95, 113, 129-132,254). On the other hand, some findings indicate a preferential
involvement of the left (197,306) or the right hemisphere (239). In addition, early onset
cases of AD have been associated with a greater prevalence of a left (247,306) or right
( 148) hemispheric dysfunction compared to late onset AD cases. Other studies have found
no correlation between a hemispheric dysfunction and the severity of the illness, suggesting
that if there is a laterality in AD it reflects subtypes of the disease more than a generalized
phenomena (197,239).
Overall, we have demonstrated reproducible histopathological effects of intraamygdaloid injections of AP 25-35 that in young inbred male Fischer-344 rats are found
primarily within the right amygdala and hippocampus. The same brain regions within the
left hemisphere are significantly less affected. These findings support the use of this rat
model as a reliable tool to screen drugs that may alter the initial pathological events
associated with deposition of AP fibrils containing the same p-sheet structure that is
observed in senile plaques in AD. It may serve as a relatively inexpensive and efficient tool
to screen drugs that may interfere with the fibrillogenesis of Ap, enhance its degradation,
and/or attenuate its toxicity. Furthermore, identification of the cause for the lateralized
effect of AP 25-35 may prove valuable for understanding the etiology of AD and provide
possible therapeutic strategies designed to slow the progression of AD.

CHAPTER V

TIME COURSE OF THE HISTOPATHOLOGICAL EFFECTS OF INJECTIONS OF AMYLOID-P
25-35 INTO THE AMYGDALA OF YOUNG MALE FISCHER RATS

Abstract

To examine the time course of the histopathological effects of bilateral injections of
amyloid-P 25-35 (AP) and to determine if these effects are associated with a reduction in
choline acetyltransferase (ChAT) activity and behavioral impairments, we injected AP (5.0
nmol) into the amygdala of young male Fischer rats. Control rats received vehicle infusions.
For histological analysis, animals were sacrificed at 8, 32, 64, 96 and 1 28 days
postoperatively (n = 21-33 per timepoint). AP induced neuronal tau-2 staining in the right
amygdala and hippocampus but not in the same brain regions within the left hemisphere.
AP also induced reactive astrocytosis and neuronal shrinkage within the right hippocampus
and amygdala, respectively. As with tau-2, the same brain regions within the left
hemisphere in the AP treated rats were significantly less affected. In addition, AP appeared
to induce microglial and neuronal interleukin-1 p staining. The histopathological effects of AP
peaked at 32 days postoperatively. These effects were not associated with a reduction in
amygdaloid ChAT activity at 32 days postinjection. In a separate experiment, behavioral
effects of bilateral intra-amygdaloid injections of AP were analyzed at 34-52 days
postoperatively. In the open field, the treatment groups differed only in the numbers of rears
emitted. AP treated rats emitted significantly more rears than vehicle treated rats
(p = 0.016). There was no effect of AP in the Morris water maze or in the acquisition and
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retention of a one-way conditioned avoidance response. These data suggest a laterality in
the histopathological effects of

A~

and that the effects of single injections are in part

transient. These findings also suggest a direct association between plaque and tangle
formation in Alzheimer's disease (AD), and support the use of this rat model to screen drugs
that may alter the initial pathological events associated with AD, that occur before the
manifestations of extensive behavioral impairments.
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Introduction

The histopathological characteristics of Alzheimer's disease (AD) include senile
plaques, reactive astrocytes and microglia, neurofibrillary tangles, neuronal shrinkage and
cell loss in several brain regions. Senile plaques consist predominantly of amyloid-P (Ap) 142 (103,214,233,285). It is derived from a large membrane spanning protein, the amyloidp precursor protein (APP) (166), and is thought to play an important role in the pathogenesis
of AD. Mutations in APP in some forms of familial AD ( 104,242) are associated with an
elevated production of AP (33,39,331 ). APP is overexpressed in Down's syndrome
(248,291) and individuals with this disease invariably develop the neuropathological
hallmarks of AD (23, 1 87). Senile plaques appear at a younger age than do neurofibrillary
tangles in Down's syndrome ( 100,212,291,358), suggesting that AP may have a role in
tangle formation. The main component of neurofibrillary tangles is paired helical filaments
( 168,335), which consist largely of the microtubule associated protein tau in an abnormal
state of phosphorylation (171, 182,355,356). In vitro (26,207) and in vivo
(91, 178, 180,315,317) studies have demonstrated that AP induces abnormal tau
immunoreactivity (IR), suggesting an association between plaque and tangle formation in
AD. The distribution of plaques and tangles in AD is such that AP deposits are often
located at the nerve terminals of neurons that contain tangles. This suggests that AP may
act on nerve terminals to cause cytoskeletal alterations in axons that ultimately lead to
tangle formation within the perikarya (265). This notion is supported by the observation
that the APP is predominantly located in the synaptic zone of neurons (301 ).
The proposed role for AP in the pathogenesis of AD is further supported by the
neurotoxicity of AP in vitro (369,370), that includes amino acids 25-35 of the peptide
(370). AP toxicity in cell culture (273,284,368-370) depends on its aggregation state
(25,220,269,273), and requires the assembly of AP into amyloid fibrils composed of a P-
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pleated sheet structure (26, 144,203). The reproducibility of Aj3 toxicity in vivo has been
inconsistent (42,91,99, 101, 102, 178, 180,314,315,317,320,354). This may be due to
variations in: 1) the conformational state (25,269,273), dose, and sequence of Aj3; 2)
method of administration; 3) pathological endpoints measured; 4) what brain region and/or
hemisphere is injected; 5) postoperative interval; and, 6) species and/or strain used.
The transformation of resting astrocytes to reactive astrocytes is one of the earliest
and most predominant responses of the central nervous system (CNS) to tissue injury. In
the AD brain, reactive astrocytes are found in high abundance surrounding senile plaques
(70, 126, 128,250). They colocalize with plaques at a relatively early stage in AD and
apparently prior to the appearance of plaque associated dystrophic neurites (270). Glial
fibrillary acidic protein (GFAP) (77) is a component of the glial intermediate filaments that
form part of the cytoskeleton, and is found predominantly in astrocytes. GFAP levels in AD
brains are increased 8 to 16 fold compared to control brains (21,60). Recent reports
suggest that Aj3 induces reactive astrocytosis in vitro (34, 141,271) and we have
demonstrated a similar effect in vivo (315,317).
Microglia are the brain's representatives of the immune system and express many
leukocyte surface antigens, which are upregulated in AD (227). In the AD brain, microglia
are known to associate with plaques (122, 155,228), and inflammatory cytokines found in
senile plaque regions include interleukin (IL) 1, IL-6, and tumor necrosis factor
(62, 117,309). Microglia seems to be the major source of IL-1 within the CNS, but this
cytokine is also found in astrocytes and neurons (300). In rat, mouse, human and other
species, IL-1 exists in two forms, IL-1 a (199) and IL-1 j3 (9) that are the products of two
separate genes (40,97). Human IL-1a and IL-1 j3 have 25% homology and appear to have a
similar biological activity (63). IL-1 j3 in vitro stimulates the APP promoter (64), induces APP
mRNA (59,89, 108), stimulates production of the secreted form of APP (31 ), and enhances
Aj3 cytotoxicity in PC12 cells (82). Conversely, Aj3 in vitro induces IL-1 j3 mRNA in astroglial
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cells (59), enhances astro- and microglial secretion of IL-1 (4), and stimulates the
proliferation and morphological transformation of microglia (4).
Relatively few studies have investigated the effects of A~ injections on behavior and
the experimental procedures vary substantially
(41,65,85, 102,221,223,224,244,314,334,354). Most of these studies have shown that
intracerebral injections of

A~

cause behavioral alterations, except a study using the rat

(354) and a report where

A~

by itself had no effect but potentiated the behavioral

A~

impairments induced by ibotenic acid (65). We have also previously reported that injections
of

A~

into the basal forebrain had no significant behavioral effects (314).
The major pathological changes in AD are in regions of the medial temporal lobe,

including the hippocampus, amygdala, entorhinal cortex and parahippocampal gyrus (265).
Among these brain regions, the number of senile plaques has been reported to be highest in
the amygdala (8). Some reports indicate that the amygdala is affected earlier in the disease
than the hippocampal or cortical areas (158,258). Previously, we have observed that single
A~

25-35 injections (5.0 nmol) into the right amygdala of rats produce progressive (8 vs. 32

days) cytoskeletal and astrogliotic reactions within the amygdala, and at distant brain
regions that project to the amygdala (317). We have also reported on the laterality in the
histopathological effects of bilateral intra-amygdaloid injections of

A~

25-35 at 32 days

postoperatively (315). To examine the time course of the histopathological effects of
bilateral injections of

A~

and to determine if these effects are associated with a reduction in

choline acetyltransferase (ChAT) activity and behavioral impairments, we injected

A~

(5.0

nmol) bilaterally into the amygdala of young male Fischer-344 rats. The data for the A~
deposits, tau-2 IR, reactive astrocytosis and neuronal shrinkage at 32 days postoperatively
has been previously reported (31 5).
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Materials and Methods

Animals
Male Fischer-344 rats were obtained from the NIA colony at Harlan Sprague-Dawley
(Indianapolis, IN). At the time of arrival, the rats weighed 250-300 g and were 3-4 months
of age. The animals were housed individually, maintained on a 12 h light-dark cycle (lights
on at 07:00 h) in a AAALAC approved facilities, had access to food and water ad libitum,
and were habituated to their new environment for 2-3 weeks prior to surgery.

Suraery
Surgery was performed under sodium pentobarbital (50 mg/kg, intraperitoneally
(i.p.); Butler, Columbus, OH) anesthesia. Atropine sulfate (0.4 mg/kg; Sigma, St. Louis,
MO) and ampicillin sodium salt (50 mg/kg; Sigma) were injected intramuscularly once the
animals were anesthetized. The animals received a bilateral injection of 5.0 nmol into each
amygdala. Some of the animals were injected first into the right amygdala and subsequently
into the left amygdala, while others were injected simultaneously into the left and right
amygdala. A Kopf stereotaxic instrument was used with the incisor bar set at 3.3 mm
below the interaural line. Injection coordinates measured from the bregma and the surface
of the skull (AP - 3.0, ML ± 4.6, DV - 8.8) were empirically determined based on the atlas
of Paxinos and Watson (261 ). A volume of 3.0 µI was administered over 6 min (flow rate
0.5 µI/min) using a CMA/100 microsyringe pump (Carnegie Medicin AD, Solna, Sweden).
The cannula was left in situ for 2 min following injection, and then was slowly withdrawn.
Following surgery the animals were placed on a heating pad until they regained their righting
reflex.
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AP 25-35 and AP 35-25 (BACHEM, Torrance, CA) were supplied as trifluoroacetic
acid (TFA) salts. At the time of surgery, information was not available from the supplier
regarding the amount of TFA per mg of the salt of the peptide. According to the supplier,
there is not a direct stoichiometric relationship between the content of AP 25-35 and TFA,
in other words it is not known how many mol of TFA there are in each mol of the TFA salt
of AP 25-35. The peptide content was 77% ( ± 3%) with the remaining 23% consisting of
TFA and H 2 0, and the purity of the peptide was

> 98%. We assumed that there are 2 nmol

of TFA per 1 nmol of AP 25-35, that is TFA content of 16.7% per mg of the salt. Recent
information from the supplier indicates that the TFA content is actually 9.7%. The peptide
and its respective vehicle (VEH; TFA, sodium salt; Sigma) were dissolved in Nanopure®
water (H 2 0) immediately before use and stored at 4°C between injections.

Animal Sacrifice and Tissue Preparation
For histological analyses, animals were anesthetized with sodium pentobarbital ( 1 00
mg/kg, i.p.), perfused transaortically at 8, 32, 64, 96 or 128 days postoperatively and the
brains processed as previously described (317). Serial coronal sections (40 µm) were cut
and five series of sections at 0.2 mm intervals were saved for histological analysis of 1)
cresyl violet, 2) tau-2, and 3) GFAP staining. Also, selected series were stained with IL-1 P
and Congo red. The first series was immediately mounted on slides, dried, and stained with
cresyl violet. The other series were placed in ethylene glycol cryoprotectant and stored at 20°C until used for immunohistochemistry.
For neurochemical analysis (ChAT activity), the animals were sacrificed by
decapitation between 09.00-15.00 h in an area outside the animal room. The brains were
removed and dissected over ice using a modification of the method detailed by Heffner et al.
(133). Accordingly, serial 2.0 mm coronal sections were obtained. The amygdaloid
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complex (4.0 mm) was obtained, frozen on dry ice and stored at -80°C until assayed.
Extensive histological analysis was not performed on the rats that were tested behaviorally
but appropriate cannula placement and

A~

deposition was verified in several animals.

Histology
Cresyl violet and Congo red: Mounted sections were defatted in xylene and
hydrated in ethyl alcohol and water series. Cresyl violet staining was performed as
previously described (317). Congo red staining was performed for 1 h in a 50% ethanol
solution containing 1 % Congo red. The sections were then dipped in saturated lithium
carbonate for 1 5 sec and subsequently washed in running water for 1 5 min.
Counterstaining was performed in Harris hematoxylin for 2 min, the sections were then
rinsed in running water, and differentiated in 1 % acid alcohol. Subsequently, the sections
were washed in running water, dipped in ammonia water, and again washed in running
water. The sections were then dehydrated in ethyl alcohol series and cleared in xylene. The
tissue was subsequently covers lipped using a DePeX mounting medium.

Tau-2 and GFAP: Staining was performed as previously described (317). Briefly,
sections (40 µm) were incubated in tau-2 (Sigma, St. Louis, MO) primary antibody at a
1 :500 dilution for 24 h at room temperature. An anti-mouse immunoglobulin (lg) G
secondary antibody (Vectastain ABC Elite kit, Vector Laboratories, Burlingame, CA) was
used at a 1 :2000 dilution. GFAP staining was performed the same way as the tau-2
staining. The GFAP antibody (Dako, Denmark) was used at a 1 :500 dilution. The
secondary antibody was a goat anti-rabbit lgG (Vector) diluted 1: 1333. Omit sections for
tau-2 and GFAP were obtained by omitting the primary antibody. According to product
specifications, the biotinylated anti-mouse lgG (Vector) has 25% cross-reactivity with rat
lgG. We were able to reduce this non-specific staining by diluting the secondary antibody.
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lmmunolabelled neurons in the omit sections were subtracted accordingly to establish a
baseline.

!1.:.1..lt

Performed the same way as GFAP staining. The anti-rat IL-1 ~ (Endogen,

Cambridge, MA) was used at a 1 :250 dilution. The secondary antibody was a goat antirabbit lgG (Vector) diluted 1: 1333.

Behavioral Analyses
Animals were handled daily beginning four days prior to the first behavioral
experiment, and daily throughout the experiments.

Open Field Activity: The open field was used to measure a neophobic response and
subsequent exploratory behavior. The dimensions of the open field were 1 00 cm x 100 cm
x 40 cm high. The walls were composed of varnished plywood. The floor was painted flat
white and divided by thin black lines into 25 squares (20 x 20 cm). Four equidistantly
spaced holes (3.5 cm diameter) were located in the four corner squares of the central nine
squares. The open field was located in a sound-attenuated dark room and was illuminated
by two 15 W fluorescent tubes positioned adjacent to the chamber, as well as by a 25 W
fluorescent tube located under the elevated (7. 5 cm) floor of the chamber. The animals
were placed in the open field for 1 2 min and their behavior analyzed by means of a video
monitor. The following behaviors were quantified: ( 1) the time to leave the center squares,
(2) the number of wall and center squares entered, (3) the number of rears, (4) the number
of nose pokes, and (5) the number of fecal boli.

One-Way Conditioned Avoidance Response !CAR): One-way avoidance conditioning
is a spatial (place) learning and memory task that is motivated by an aversive unconditional
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stimulus. The chamber was comprised of two identical compartments (50 cm long, 24 cm
wide, and 30 cm high) separated by a 7.0 cm high serrated metal hurdle (0.5 mm thick).
The ceiling, rear, and end walls were composed of white opaque plastic (Perspex) whereas
the front wall was made of transparent Perspex. The grid floor consisted of stainless steel
rods (3.0 mm diameter) spaced 1.0 cm apart. Illumination was provided by a 25 W
fluorescent tube mounted outside the rear wall. A Grason-Stadler control panel and shock
generator were used to deliver scrambled continuous constant-current (0.8 mA) shock.
Each animal was placed in the apparatus, close to and facing the end wall of the
"shock" compartment. After a delay of 5.0 sec, continuous shock was delivered until the
rat crossed the hurdle and entered the opposite side of the apparatus (the "safe"
compartment). If a rat failed to escape the shock within 15 sec, it was placed in the safe
compartment. The animal was left undisturbed for 20 sec, unless it returned to the "shock"
compartment. If so, shock was delivered until the rat re-entered the "safe" compartment.
After spending 20 sec in the "safe" compartment, the rat was removed from the apparatus
and placed in its home cage for 5.0 sec, before the start of the next trial. Crossing the
hurdle within 5.0 sec after placement in the "shock" compartment was scored as an
avoidance response. Response latency was measured automatically by an elapsed timer.
Testing was continued until criterion (9 avoidance responses in 10 consecutive trials) was
attained. If a rat returned within 20 sec to the "shock" compartment after having made a
CAR, the preceding CAR was not included as one of the criterion trials. Failure to enter the
"safe" compartment before shock was delivered and returns to the shock compartment were
scored as errors. All the rats reached criterion in a single session.
Retention of the one-way CAR task was examined 2 weeks later. The rats were
treated in the same manner as during the acquisition phase and tested until criterion was
attained.
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Morris Water Maze: Spatial learning and memory were tested in the Morris water
maze task. The maze consisted of a circular plastic tub (152 cm in diameter and 74 cm
deep), painted flat white. A platform (9 cm in diameter) was placed halfway between the
center of the pool and the edge, 1.5 cm below the surface of the water. The water (56 cm
deep) in the pool was made opaque by the addition of powdered milk, and its temperature
was 19-21 °C. Extra maze cues were plentiful and kept consistent throughout the entire
experiment. Data was gathered with a video tracking system (Chromotrack 3.01 a, San
Diego Instruments, San Diego, CA). A small video camera linked to a computer was
mounted directly over the center of the maze. A small black dot was painted on the
animal's head with a non-toxic marker because the camera visualizes a dark object on a light
field. The computer calculated the animal's path length to platform and the latency to find
the platform.
The animals were given 4 trials a day for 5 consecutive days, or a total of 20 trials.
On each trial the animal was placed into the pool close to the edge in the middle of a
quadrant. The first 4 days, the platform was located in the same quadrant. The 5th day,
the platform was moved to the opposite quadrant. On the first trial the animal was placed
into the pool in a quadrant next to the platform. In the 3 subsequent trials the animals were
placed into the pool in the adjacent quadrants in a clockwise manner. A trial continued until
the animal climbed onto the platform, or until 60 sec had elapsed. It was left on the
platform for 60 sec prior to the start of the next trial. Upon completion of all four trials the
rat was removed from the maze, dried with a towel and returned to its cage.

Neurochemical Analysis
Frozen brain tissue (-80°C) was weighed, thawed at 4°C and homogenized in icecold sodium phosphate buffer (75 mM, pH 7.4). ChAT activity was measured using a
modification of the method of Fonnum (86). Briefly, 10 µI of homogenate were added to 10
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µI of buffer substrate mixture. The mixture contained 49 volumes of buffer substrate
(sodium phosphate, 75 mM, pH 7.4; NaCl, 600 mM; MgCl 2 , 40 mM; eserine, 2.0 mM;
bovine serum albumin, 0.05%; choline iodide, 10 mM; and acetyl-CoA, 0.87 mM) and 1
3

volume of [ H]acetyl-CoA (200 mCi/mmol, 0.5 mCi/ml; Du Pont NEN®, Boston MA). The
samples were incubated for 30 min at 37°C, and then placed on ice. Newly synthesized
radiolabelled acetylcholine (ACh) was extracted into 1 50 µI of sodium tetraphenylboron
solution (75 mg/ml in 3-heptanone). The tubes were vortexed and after centrifugation, 100
3

µI of the organic layer were taken to measure [ HJACh using liquid scintillation spectrometry.
The amount of radioactivity extracted from buffer, incubated in parallel, without tissue, was
subtracted as blank. Activities were measured in triplicates. Protein measurements, in
duplicates, were performed according to Lowry et al. (204).

Data Analysis
An image analysis system (NIH Image 1 .49) was used to determine the size of the
A~

deposits and neuronal shrinkage within the left and right amygdala at different

timepoints. The area of the

A~

deposits was measured at 0.2 mm intervals. These data

failed a normality test and were, therefore, analyzed by a two-way analysis of variance
(ANOVA) on ranks (SIGMASTAT, version 1.01; Jandel, San Rafael, CA) followed by a
Newman-Keuls' multiple range test for post hoc comparisons. Quantitative analysis was
performed on the cresyl violet stained sections at 32 and 1 28 days postinjection. The
basolateral nucleus within the amygdala can be divided into parvicellular and magnocellular
subnuclei based on the cytoarchitecture of the neurons. The cells within these subnuclei
have a relatively uniform appearance and their boundaries are easily identified. The
magnocellular division is located mainly rostral and medial to the parvicellular division. The
area of 1 O of the largest magnocellular cells (X400 magnification) within the left and right
basolateral amygdala was measured in one cresyl violet stained section per animal slightly
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rostral to the injection site, and we carefully chose sections at a similar coronal level. The
average area of these 10 cells was calculated. The data based on this average cell area
failed a normality test and were, therefore, analyzed by a two-way ANOV A on ranks
followed by a Newman-Keuls' multiple range test for post hoc comparisons. Neuronal tau-2
IR in the left and right amygdala and hippocampus, and reactive astrocytosis in the left and
right hippocampus were rated on a scale of 0-2 +. An animal was considered positive if it
exhibited

~

1 + staining. These data were analyzed using a Fisher exact test, one-tail

(SIGMASTAT). No statistical difference was discerned between the VEH groups at each of
the timepoints so they were combined in the subsequent analysis. The rating of the tau-2
sections was based on the number of IR cells (X400 magnification), relative to omit
sections, within the amygdala or hippocampus in a section at the injection site (0 = 0-5
cells/section; 1 + = 6-50 cells/section; 2 + =

> 50 cells/section). The brain region that had

higher cell counts was used for analysis. We have previously demonstrated (315) that there
is a significant correlation between the number of tau-2 IR neurons within the amygdala and
hippocampus (r=0.833, p<0.001). The rating of the GFAP sections was based on the
complexity of astrocytic branching within the hippocampus (0 =resting astrocytes, few
processes; 1 + = reactive astrocytes, moderate branching; 2 + = reactive astrocytes,
extensive branching). In addition, a more detailed analysis of tau-2 IR was performed at 32
and 128 days postoperatively. Tau-2 IR neurons were counted in the left and right
amygdala in six sections surrounding the injection site, and in six hippocampal sections
including and caudal to the injection site. Tau-2 IR neurons were also counted in omit
sections and subtracted accordingly. These data failed a normality test and, therefore, were
analyzed using a two-way ANOVA on ranks for the amygdala and hippocampus separately,
followed by a Newman-Keuls' multiple range test for post hoc comparisons. No statistical
difference was discerned, in any of the parameters analyzed, between rats injected first into
the right and subsequently into the left amygdala, and animals injected simultaneously into
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the left and right amygdala, so they were combined in the subsequent analyses. The open

field and the CAR data were analyzed by a t-test or a Mann-Whitney rank sum test when the
data failed a normality test (SIGMASTAT). The Morris water maze data, when the platform
was in its original position, was analyzed by a two-way ANOV A with repeated measures on
one factor (days) followed by a Newman-Keuls' post hoc test (SIGMASTAT). At-test was
used to analyze the water maze reversal data. The ChAT activity data was analyzed by a
two-way ANOV A on ranks because the data failed a normality test.

Experimental Design
Experiment 1: Histological effects of

A~

25-35 at 8, 32, 64, 96 and 128 days

postoperatively. The rats were injected first into the right amygdala and subsequently into
the left amygdala, or simultaneously into the left and right amygdala. The dose of AP 25-35
was 5.0 nmol/3.0 µI H 2 0 (each side). VEH treated animals were injected with 10.0 nmol
TFA/3.0 µI H 20 (each side).
n

Days

Treatment

9

8

VEH

2

12

8

AP 25-35

3

13

32

VEH

4

20

32

AP 25-35

5

13

64

VEH

6

19

64

AP 25-35

7

11

96

VEH

8

16

96

AP 25-35

9

11

128

VEH

10

17

128

AP 25-35

Group#
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Experiment 2: Behavioral effects of bilateral intra-amygdaloid injections of Aj3 25-35
at 34-52 days postoperatively. The same dose was used as in Experiment 1 (5.0 nmol/3.0
µI).

Group#

2

n

Treatment

10

VEH

13

Aj3 25-35

Experiment 3: Effects of bilateral intra-amygdaloid injections of Aj3 25-35 (5.0
nmol/3.0 µI) on ChAT activity in the amygdala at 32 days postinjection.

n

Treatment

5

VEH

2

5

Aj3 35-25

3

6

Aj3 25-35

Group#
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Results

Experiment 1: Histological Effects of AB 25-35 at 8. 32. 64. 96 and 128 Days
Postoperatively.

AB deposits
Proteinaceous deposits were observed bilaterally in the amygdala of the AJ3 25-35
rats (Figures 16, 17). The location of the deposits did not vary between the left and right
amygdala. The deposits were found consistently at the injection site immediately medial to
the basolateral nucleus. The size of the deposits appeared to be less than the overall
volume of the basolateral nucleus. These deposits were Congo red positive (apple-green
birefringence under polarized light) similar to those we have observed following AJ3 25-35
injections into the ventral pallidum/substantia innominata (VP/SI) (314), and into the right
amygdala (317). These deposits were seen in animals at all timepoints (8-128 days; Figure
17). Ninety percent of the injections resulted in AJ3 deposits at the time of sacrifice. Twoway ANOV A of the area of these deposits within the left and right amygdala at different
timepoints revealed a significant difference between the left and right amygdala [F( 1,
158) = 5.261, p =0.0231 but there was no difference between timepoints [F(4,
158) = 1.774, p =0.137], and no interaction between the two factors [F(4, 158) = 1.013,
p = 0.402]. Also, post hoc pairwise comparisons between these two factors revealed no

significant differences (Figure 17).

Figure 16. Congo red positive AJ3 deposits at 32 and 128 days postoperatively. Congo red
stained coronal sections (X160) through the left amygdala at the injection site in AJ3 25-35
treated rats at 32 days (A) and at 128 days (B) postoperatively. Note the Congo red
positive birefringence under polarized light in the AJ3 deposits at both 32 and 1 28 days
postinjection.
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Figure 17. Size of the A~ deposits within the left and right amygdala at 8, 32, 64, 96, and
128 days postoperatively. These deposits were Congo red positive (apple-green
birefringence under polarized light). Post hoc analysis of the area of these deposits within
the left and right amygdala at individual timepoints revealed no significant differences. Each
bar represents the mean+ SEM of n = 12-20 rats. LDEP: A~ deposits, left amygdala; RDEP:
A~ deposits, right amygdala.
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A semi-quantitative analysis revealed an increase in tau-2 staining that was observed
predominantly within the right amygdala or hippocampus in the A/3 infused rats at 8 days
(p<0.01), 32 days (p<0.001) and 64 days (p<0.01) postinjection, compared to the VEH
treated rats (Figures 18, 19). A/3 25-35 increased tau-2 IR in neuronal perikarya and
processes predominantly in the right amygdala and hippocampus. There also appeared to be
an increase in tau-2 IR in other brain areas within the right hemisphere, such as the
cingulate, parietal and pyriform cortices, hypothalamus, thalamus, globus pallidus,
claustrum, substantia nigra, VP/SI, and the entorhinal cortex. These cytoskeletal changes
peaked at 32 days postinjection (Figure 19). The left amygdala and hippocampus were
significantly less affected in the VEH treated animals (p<0.01 ), and the A/3 treated rats at 8
days (p < 0.05), 32 days (p < 0.001), and 64 days (p < 0.01) postoperatively.
A quantitative analysis at 32 and 128 days postoperatively revealed a similar effect
as the semi-quantitative analysis. Two-way ANOVA for the amygdaloid tau-2 IR (Figure
20A) revealed a significant difference between rats sacrificed at 32 days vs. 128 days [F(1,
112) = 6.195, p < 0.014], and between treatments and/or hemispheres [F(3, 112) = 19.234,
p < 0.001]. There was also a significant interaction between the two factors [F(3,

112) = 5.306, p = 0.002]. Post hoc pairwise comparisons between the two factors revealed
a significant difference at 32 days between the left and right amygdala in the A/3 treated rats
(p<0.01) and in the right amygdala between the VEH and A/3 treated rats (p<0.01). Also,
in the A/3 infused rats the number of tau-2 IR neurons within the right amygdala differed at
32 days vs. 128 days postoperatively (p<0.01 ). A similar pattern was observed within the
hippocampus (Figure 208). Two-way ANOVA for the hippocampal tau-2 IR revealed a
significant difference between rats sacrificed at 32 days vs. 128 days [F(1, 112) = 4.910,
p < 0.029], and between treatments and/or hemispheres [F(3, 112) = 8. 701, p < 0.001].

There was also a significant interaction between the two factors [F(3, 112) = 5.248,
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p = 0.002]. Post hoc pairwise comparisons between the two factors revealed a significant

difference at 32 days between the left and right hippocampus in the A~ treated rats
(p<0.01) and in the right hippocampus between the VEH and A~ infused rats (p<0.01 ).
Also, in the A~ treated rats, the number of tau-2 IR neurons within the right hippocampus
differed at 32 days vs. 128 days postoperatively (p < 0.01).

Figure 18. Tau-2 IR at 32 days postinjection. Tau-2 stained coronal section through the left
(A) and right (C) hippocampus (X63), and the left (8) and right (D) amygdala (X63) in a rat
injected bilaterally with A~ 25-35. E (X160) and F(X250) are magnifications of the areas
bracketed in C and D, respectively. The hippocampal sections are substantially caudal ( 1. 5
mm) to the injection site. The amygdaloid sections are at the injection site, where A~
deposits (arrows in B and D) are visible. No tau-2 IR is observed within the left
hippocampus (A) or the left amygdala (8). Note the neuronal tau-2 IR within the right
hippocampus (C, E) and the right amygdala (D, F) in this same animal. This rat represents a
rating of 0 in the left hippocampus and amygdala, and a rating of 1 + in the right
hippocampus and amygdala.
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Figure 19. Time course of neuronal tau-2 IR within the left and right amygdala or
hippocampus. Note the transient induction in tau-2 IR within the right amygdala or
hippocampus in the A~ treated rats. Note the lack of AP effect within the left hemisphere
compared to the right hemisphere. No statistical difference was discerned between the VEH
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of AP in the right amygdala or hippocampus compared to VEH treated rats: * *p < 0.01;
* * * p < 0.001. Effects in the right amygdala or hippocampus compared to the left amygdala
or hippocampus: #p<0.05; ##p<0.01; ###p<0.001.
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Figure 20. Neuronal tau-2 IR within the left and right amygdala (A) and hippocampus (B) at
32 and 128 days postinjection. Each bar represents the mean+ SEM of tau-2 IR neurons
from 6 sections (40 µm). The bars for the VEH treated rats at 32 and 1 28 days represent
n = 1 3 and 11, respectively. The bars for the A~ treated rats at 32 and 1 28 days represent
n = 1 9 and 17, respectively. Effects of A~ at 32 days in the right amygdala or hippocampus
compared to VEH treated rats: * * p < 0.01. Effects of A~ at 32 days in the right amygdala
or hippocampus compared to the left amygdala or hippocampus: ##p < 0.01. Effects of A~
in the right amygdala or hippocampus at 32 vs. 128 days: AAp<0.01.
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Reactive astrocytosis (Figures 21, 22) was observed predominantly within the right
hippocampus in the AP treated rats at 8 days (p<0.001), 32 days (p<0.001 ), 64 days

(p < 0.01), and 96 days (p < 0.05) postinjection, compared to VEH treated rats. The left
hippocampus was significantly less affected in the VEH treated animals (p < 0.01 ), and the
AP treated rats at 8 days (p<0.01), 32 days (p<0.001), and 64 days (p<0.01)
postoperatively. These histological changes peaked at 32 days postoperatively, and were
seen most consistently within the right hippocampus although other areas of the right
hemisphere appeared to be also affected.

Figure 21. GFAP IR at 32 and 128 days postinjection. GFAP stained coronal sections
(X25) through the left (A) and right (8) hippocampus in a bilaterally injected AP 25-35 rat at
32 days postoperatively, and through the right hippocampus (C) in a bilaterally treated AP
25-35 rat at 128 days postinjection. D represents the right hippocampus in a VEH treated
rat at 32 days postoperatively. E, F, G, and H are magnifications of the areas bracketed in
A, 8, C, and D, respectively. Reactive astrocytosis is moderate in the left hippocampus (A,
E), whereas prominent reactive astrocytosis is observed in the right hippocampus (8, F). No
effect is observed in the AP 25-35 treated rat at 128 days (C, G) or in the VEH treated rat
(D, H). The AP 25-35 infused rat at 32 days postinjection represents a rating of 1 + in the
left hippocampus and a rating of 2 + in the right hippocampus. The AP 25-35 treated rat at
1 28 days postinjection and the VEH injected rat at 32 days postoperatively represent a
rating of 0 in the right hippocampus.
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Figure 22. Time course of reactive astrocytosis within the left and right hippocampus. Note
the transient induction in reactive astrocytosis within the right hippocampus in the Af3
treated rats. Note the lack of Af3 effect within the left hippocampus compared to the right
hippocampus. No statistical difference was discerned between the VEH groups at each of
the timepoints (n = 9-13) so they were combined (n = 58) in the subsequent analysis. The
bars for the Af3 treated rats represent n = 12-20. The data are presented as the percentage
of positive rats (rating of ~1 +) of total rats analyzed. Effects of Af3 in the right
hippocampus compared to VEH treated rats: *p<0.05; **p<0.01; ***p<0.001. Effects
in the right hippocampus compared to the left hippocampus: ##p < 0.01; ###p < O.b01.
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Cresyl violet (CV)
All nuclei within the right amygdala appeared to be shrunken in the

A~

treated rats

but the atrophy was most obvious in the large magnocellular neurons within the basolateral
amygdala (Figure 23). A quantitative analysis was performed at 32 and 128 days
postinjection of the area of 10 of the largest magnocellular cells within the basolateral
amygdala (Figure 24). Two-way ANOVA revealed a significant difference between rats
sacrificed at 32 days vs. 128 days [F( 1, 114) = 43.480, p < 0.001], and between treatments
and/or hemispheres [F(3, 114) = 13.664, p < 0.001]. There was not a significant interaction
between the two factors [F(3, 114) = 2.332, p<0.078]. Post hoc pairwise comparisons
between the two factors revealed a significant difference at 32 days between the left and
right amygdala in the

A~

treated rats (p < 0. 01 , 33 % reduction in average cell area) and in

the right amygdala between the VEH and
in the

A~

A~

treated rats (p<0.01, 30% reduction). Also,

treated rats the cell area at 32 days vs. 1 28 days differed in the left (p < 0. 01 ) and

right amygdala (p < 0.01 ). Furthermore, in the

A~

injected rats at 128 days the cell area

within the right amygdala (13% reduction) differed from that in the left amygdala (p<0.05).
The neuronal atrophy appeared to extend into other brain regions within the right
hemisphere, such as cortical areas. Cell bodies within the hippocampus overlapped and,
therefore, analysis of cell shrinkage was not performed in that brain region. The
neuronal shrinkage did not appear to be associated with extensive neuronal loss.

A~

induced
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Figure 23. Cresyl violet staining at 32 days postinjection. Cresyl violet stained coronal
section (X63) through the left (A) and right (B) amygdala slightly rostral to the injection site
in a bilaterally injected A~ rat, at the level of cell area measurements. C and D are
magnification (X250) of the areas bracketed in A and B, respectively . Note the neuronal
shrinkage within the right (B, D) as compared to the left basolateral nucleus (A, C). In this
animal, the average area of 10 of the largest magnocellular cells was 1 986 ± 1 87 (SD) in the
left nucleus, and 1016 ± 178 in the right nucleus.
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Figure 24. Neuronal shrinkage in cresyl violet stained sections within the right amygdala vs.
the left amygdala at 32 and 128 days postoperatively. Each bar represents the mean + SEM.
The bars for the VEH treated rats at 32 and 128 days represent n = 13 and 11, respectively.
The bars for the A~ treated rats at 32 and 128 days represent n = 20 and 1 7, respectively.
Note the neuronal shrinkage within the right but not the left amygdala in the A~ treated rats
at 32 days and the partial reversibility of the effect of A~ at 128 days postinjection. Effects
of A~ in the right amygdala compared to VEH treated rats: * *p < 0.01. Effects of A~ in the
right amygdala compared to the left amygdala: #p<0.05; ##p<0.01. Effects of A~ in the
left and right amygdala at 32 days vs. 128 days:
p < 0.01.
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IL-1 ~ IR was predominantly observed in microglia but a less intense neuronal
staining also was evident (Figure 25, 26). The microglia were seen in the vicinity of the
cannula track, particularly at the injection site within the amygdala. Microglia were also
prominent in the alveus and the molecular layer of the left hippocampus, and in the
ependymal lining of the ventricles. In the
infiltrated the

A~

A~

injected rats, these microglia surrounded and

deposits bilaterally in the amygdala. Reactive microglia appeared to be

more prominent within the left than the right hippocampus at 8 and 32 days postoperatively
in the

A~

treated animals. Laterality also was observed in neuronal IL-1 ~ staining. Neuronal

staining appeared to be minimal in VEH treated rats. In

A~

treated rats, there appeared to

be an evenly distributed induction in neuronal IL-1 ~ staining within the left amygdala and
hippocampus. Minimal neuronal staining was observed within the right amygdala in the A~
treated rats but several neuronal perikarya stained intensely within the right hippocampus.
Further, the pattern of the most intensely IL-1 ~ stained neurons within the right
hippocampus appeared to be similar to that of tau-2.
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Figure 25. Amygdaloid IL-1 j3 IR at 32 days postinjection. Coronal sections (X25) through
the injection site in the left (A) and right (8) amygdala in an Aj3 25-35 treated rat, and
through the right amygdala in a VEH treated rat (C). Aj3 deposits are visible in A and 8
(arrows), and the injection site in a VEH treated rat is visible in C (arrow). D, E, and Fare
magnifications (X160) of the areas bracketed in A, 8, and C, respectively. Intense
microglia-like IR (arrows in D and E) is observed surrounding and infiltrating the Aj3 deposits
both within the left (A, D) and right (8, E) amygdala. Note the more intense neuronal
staining within the left amygdala (arrowheads in D), than in the right amygdala (arrowheads
in E). Very little IL-1 j3 IR is observed in the VEH treated rat, except for a few microglia-like
processes (arrow in F) at the tip of the injection site.
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Figure 26. Hippocampal IL-113 IR at 32 days postinjection. Coronal sections (X63) at the
level of the injection site in the left (A) and right (8) hippocampus in an Aj3 25-35 treated
rat, and in the right hippocampus in a VEH treated rat (C). D, E, and Fare magnifications
(X250) of the areas bracketed in A, 8, and C, respectively. In the Aj3 25-35 treated rat,
intense microglia-like IR (arrow in A) is observed in the alveus and the molecular layer of the
left hippocampus (A) but not the right hippocampus (8). Also, moderate and evenly
distributed induction in neuronal staining is observed within the left hippocampus (A, D) that
is associated with microglia (arrow in 0). More intense (arrow in E) unevenly distributed
neuronal staining is observed within the right hippocampus (8, E). Minimal IL-113 IR-is
observed in the VEH treated rat (C, F).
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Experiment 2: Behavioral Effects of Bilateral Injections of AB 25-35 34-52 Days
Postoperatively.

Animals were injected bilaterally into the amygdala with A~ 25-35 (5.0 nmol/3.0 µI;
n = 13) or its respective VEH (3.0 µI; n = 10). Behavior in the open field (Figure 27 A, B) and
the acquisition of a one-way (spatial) CAR were analyzed 34-38 days postoperatively.
Retention of the CAR was performed 2 weeks after initial testing (Table 1 ). In addition, the
rats were tested in the Morris water maze 40-46 days postoperatively (Figure 28A, B). The
animals were sacrificed at 58 days postinjection. Extensive histological analysis was not
performed but appropriate cannula placement and the existence of

A~

deposits was verified

in several animals.
There was no significant difference between the treatment groups in the number of
center squares [VEH = 6.2 ± 1.4 (SEM);
[VEH=46.1 ±11.8;
A~=

A~=

10.8 ± 2.2; p =0.119], wall squares

A~=74.5±12.0;p=0.112],

or total squares [VEH=52.3±12.9;

85.4 ± 13.0; p = 0.091] entered. Also, no significant difference was observed in the

time (sec) to leave the center squares [VEH = 41.0±11 .6;
number of nose pokes emitted [VEH = 4.9 ± 0.8;
fecal boli [VEH = 2.1±0.8;

A~=

A~=

A~=

25.9 ± 6.8; p > 0.1], the

6.1 ± 1.1;p=0.419], or the number of

1.2 ± 0.3; p =0.532]. However, there was a significant

difference in the numbers of rears emitted [VEH = 12.8 ± 2.3; A~= 21.4 ± 2.3; p = 0.016].
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Figure 27. Behavior in the open field ( 12 min). Each bar represents the mean+ SEM. (A)
Bilateral injections of A~ 25-35 (5.0 nmol) into the amygdala did not cause a significant
difference in the number of center squares, wall squares, or total squares entered, when
compared to VEH group. (8) There was a significant difference between the treatment
groups in the numbers of rears emitted (*p =0.016), but not in the number of nose pokes
emitted.
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The one-way CAR acquisition did not reveal significant differences between the
treatment groups in the latency (sec) of the first escape, in the number of trials required for
the first CAR, in the number of trials to reach criterion, or in the number of errors committed
(Table 1 ). Also, no treatment effect was observed in the retention of the one-way CAR.

Treatment

Latency of
the first
escaQe (sec)

Trial number
of the first
CAR

Number of
trials to
reach
criterion

Number of
errors
committed

4.8± 1.4
4.9 ±0.9

4.9 ±0.5
3.8±0.5

15.0±0.4
15.5±0.7

5.8±0.3
5.7±0.3

2.9±1.0
1.4±0.2

1.1 ±0.1
1.2±0.1

10.9 ±0.3
11.8±1 .0

1.8±0.2
1.9 ±0.3

Acquisition

VEH
AP 25-35
Retention

VEH
AP 25-35

Table 1. One-way CAR acquisition and retention. The rats received bilateral intraamygdaloid injections of AP 25-35 (5.0 nmol/3.0 µI). Retention was examined two weeks
following the acquisition. The data are presented as group means± SEM.

In the water maze there was no treatment effect. There was a time effect [time to
find platform: F(3, 60) =49.505, p < 0.001; distance swum to platform: F(3, 60) = 39.088,
p

< 0.001].

In addition, a treatment x days interaction was close to being significant in the

animals' path length swum to platform [F(3, 60) = 2. 708, p = 0.0531 but not in the animals'
latency to find the platform [F(3, 60) = 1.655, p =0.186]. No difference in swim speed was
observed between the treatment groups (data not shown).
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Figure 28. Behavior in the Morris water maze. Each point represents the mean+ or -SEM
of n = 10-13. The first 4 days, the platform was located in the same quadrant. The 5th
day, the platform was moved to the opposite quadrant. Bilateral injections of A~ 25-35 (5.0
nmol) into the amygdala did not cause a significant difference in the latency to find the
platform (A) or in distance traveled to the platform (8), when compared to VEH group.
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Experiment 3: Effects of Bilateral lntra-Amyqdaloid Injections of AB 25-35 (5.0 nmol/3.0

µI)

on ChA T Activity in the Amygdala at 32 Days Postoperatively.

Two-way ANOVA did not reveal significant differences in ChAT activity between
treatment groups or hemispheres, or a significant interaction between the two factors (Table

2).

ChA T Activity (nmol ACh/h/mq protein)
Treatment

Left Amyqdala

Right Amygdala

VEH
35-25
A~ 25-35

107.0 ± 6.0
110.1±5.8
107.0±5.1

107.2±7.3
109.0±4.0
106.6 ± 5.6

A~

Table 2. Amygdaloid ChAT activity. The rats received bilateral intra-amygdaloid injections
of A~ 25-35 (5.0 nmol/3.0 µI), A~ 35-25 (5.0 nmol/3.0 µI) or their respective vehicle, and
were sacrificed 32 days postoperatively. The data are presented as group means ± SEM.
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Discussion

We have confirmed our previous finding (317), that intra-amygdaloid injection of AP
25-35 induces neuronal cytoskeletal changes and reactive astrocytosis within the amygdala
as well as at distal sites. In addition, these changes were associated with neuronal
shrinkage and alterations in IL-1 p IR. Furthermore, the histopathological effects of AP 25-35
were in part transient, and were predominantly observed within the right amygdala and
hippocampus whereas the same brain regions in the left hemisphere were significantly less
affected.
We have previously discussed the relevance of the distal histological effects of AP
25-35 to the etiology of AD (317). We have also elaborated previously on the correlation
between the laterality effects of AP 25-35, and hemispheric asymmetries in the
histopathological hallmarks, cerebral metabolism, and perfusion in AD (315).
The cytoskeletal changes observed following intra-amygdaloid injections of AP 25-35
were associated with neuronal shrinkage and reactive astrocytosis. This may simulate the
initial histopathological changes that occur in AD, and suggests a direct association between
plaque and tangle formation in AD. Reactive astrocytosis is a consistent response to
neurotoxic insults, and has been observed to reveal dose, time, and region dependent
patterns of neurotoxicity at toxicant dosages below those that cause light microscopic
evidence of cell loss or damage (255). Our findings support this because reactive
astrocytosis appeared to be a more sensitive marker of toxicity than tau-2 IR and neuronal
shrinkage although the extent, regional distribution, and reversal of these histological effects
appeared to be comparable using these three different markers.
Microglia appear to be the major source of IL-1 within the CNS, but this cytokine is
also found in astrocytes and neurons (300). AP 25-35 in vitro induces IL-1 P mRNA in
astroglial cells (59). AP 1-42 enhances in vitro astro- and microglial cell secretion of IL-1,
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and stimulates the proliferation and morphological transformation of microglia (4). These in

vitro findings are in accordance with the intense IL-1 p glial staining surrounding and
infiltrating the

AP

deposits bilaterally within the amygdala. This observation correlates with

the association of senile plaques in AD with IL-1 positive microglia (62, 117,309). Laterality
in IL-1 P IR was predominantly observed in neurons. Neuronal staining was minimal in VEH
treated rats but in

AP

treated rats there appeared to be an induction in neuronal IL-1 p IR

within the left hippocampus and amygdala that seemed to be rather evenly distributed within
the neurons. In the right hemisphere in

AP

injected rats, intense neuronal IL-1 p IR was

predominantly observed in hippocampal neuronal perikarya. Peptidergic neurotransmitters
are always synthesized in the cell bodies and then transported to the nerve terminals.
Inhibitors of axonal transport such as colchicine are often used to visualize peptide IR cell
bodies in animal brains. Because

AP

25-35 induces cytoskeletal changes it may attenuate

the axonal transport of IL-1 P and presumably other peptides. This leads to accumulation of
IL-1 p within neuronal cell bodies and a concomitant loss of staining in other neuronal
compartments, which is what our results indicate within the right hippocampus. This
hypothesis is supported by the observation that in adjacent sections from the same animal,
the pattern of hippocampal neuronal IL-1 p and tau-2 staining appeared similar. However,
double labeling of neurons with antibodies against IL-1 p and tau-2 would be necessary to
verify this scenario. This presumed reduction in neuronal IL-1 p release may exacerbate
toxicity because IL-1
(323), and

AP

P attenuates excitatory amino

AP

acid induced neurodegeneration in vitro

potentiates in vitro neurotoxicity of excitatory amino acids (218). This

scenario also suggests that the apparent induction in neuronal IL-1 P synthesis within the left
amygdala and hippocampus may attenuate
Congo red positive

AP

AP

toxicity within these brain regions.

deposits were consistently observed at the site of injection,

suggesting that these deposits retain their p-pleated sheet structure, the toxic conformation
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of AP, several months following injection into the rat amygdala. The AP deposits were
extremely resistant to degradation because volumetric analysis did not reveal significant
reduction in their size up to 128 days postinjection (Figure 17). It has been demonstrated in

vitro, that AP develops protease resistance to degradation when polymerized into fibrils
(252). Microglia in culture scavenge AP (5) and microglia-like phagocytes have a role in AP
clearance following intraventricular infusions of AP 1-40 (92). Microglial activation takes
place in a rather stereotypic pattern where there is a transformation of resting microglia into
activated cells, which in their end stage resemble phagocytic cells. We did not observe
phagocytic IL-1 p positive microglia, supporting the findings from the quantitative
measurements that the amygdaloid AP deposits are resistant to proteases that are necessary
to cleave large peptide fragments for phagocytosis to occur. The consistency and
persistence of AP deposits likely depends on several factors, such as the method of
administration, solvent, dose, volume, sequence of Ap, and brain region injected. The
presence of heparan sulfate proteoglycans has been shown to be important for consistent in

vivo deposition of AP 1-40 and persistence of fibrillar AP in the rat hippocampus (321).
Furthermore, AP 25-35 deposits within the rat nucleus basalis have been reported to be
degraded more rapidly than AP 1-40 deposits ( 102). Acetylcholinesterase (AChE) has been
demonstrated to promote the formation of and/or stabilize AP fibrils ( 1 50). This proposed
role of AChE may explain the consistency and persistence of the AP fibrils in the present
study, because the basolateral amygdala adjacent to the injection site contains very high
levels of AChE (261). Analysis of variance revealed that overall the size of the AP deposits
was greater on the left than on the right side (p =0.023), suggesting that there may be
hemispheric differences in the degradation and/or fibril formation of AP. However, post hoc
comparison of the size of the deposits at each of the postoperative intervals investigated
failed to reveal any significant differences. Therefore, these findings suggest that the
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laterality and the partially transient effects of AP can not be explained by differences in the
size of the AP deposits per se at any individual timepoint.
The histopathological effects of AP 25-35 peaked at 32 days postoperatively. This
indicates that the effects of single injections are in part transient even though the AP
deposits are resistant to degradation. Chemically induced gliosis has been shown to be
often transient in nature with the time course of both the onset and decline in GFAP varying
markedly from toxicant to toxicant (256). The AP deposits were always surrounded by
reactive microglia and astrocytes. It is likely that this encapsulation renders the deposits
biologically inert. The histological effects of AP are, therefore, likely to be initiated early
following injection, and an inflammatory response triggered by glial activation in the vicinity
of the deposits may have a role in AP induced pathology. However, it should be noted that
reactive glia were also associated with the cannula scar in VEH treated rats. Lesion studies
have demonstrated brain lateralization in immunomodulation (249). This asymmetry may in
part explain laterality in the histological changes caused by Ap, because the deposits may
act as antigens to activate the immune system. It is possible that the histological effects of
AP may not be as reversible in old animals that have compromised metabolic functions.
However, these transient effects do not exclude the use of young animals injected with AP
as a model for the initial pathological changes that occur in AD. Based on observations in
Down's syndrome patients, the histopathology in AD is likely to begin at an early age and it
is important to slow its progression in its infancy. An animal model using young rats in
which the pathological changes peak within 2 months following injection may, therefore,
serve as a relatively inexpensive and efficient tool to screen drugs that may interfere with
the fibrillogenesis of AP, enhance its degradation, and/or attenuate its toxicity.
Electrolytic lesions of the amygdaloid complex (51,73, 163,305), lesions of the
central nucleus (118, 160,350), or of the lateral and basal nuclei of the amygdala (159)
enhance exploratory behavior of rats in the open field test. No significant difference was
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observed between the treatment groups in any of the parameters examined in the open field,
except that the AP treated rats emitted significantly more rears than their respective VEH
group (Figure 278; p<0.016). Lesions of the amygdala have been shown to be associated
with behavioral impairments in active avoidance learning (30,286), but do not appear to
impair spatial learning in the Morris water maze (58,330). Lesions of the hippocampus
severely disrupt spatial learning (257,278) and this impairment has been shown to be
potentiated by amygdaloid lesions (1,267). Therefore, because intra-amygdaloid injections
of AP induce histopathological changes not only within the amygdala but also at distal sites
including the hippocampus, it was considered appropriate to use the water maze test. No
behavioral differences were observed between the treatment groups in the one-way CAR
(Table 1) or in the water maze (Figure 28 A,B). Overall, the lack of severe behavioral
impairments in this study may be explained by the lack of extensive neuronal loss and/or by
the laterality in the histopathological effects of Ap. The left hemisphere may compensate
for the impairments within the right hemisphere.
The amygdala receives a prominent cholinergic input from the nucleus basalis

(35,363), and ChAT activity has been reported to be severely reduced within the amygdala
in AD patients (258,287,288). Measurements of amygdaloid ChAT activity were performed
to investigate if the cytoskeletal changes and neuronal shrinkage within the amygdala were
associated with a reduction in ChA T activity. No differences were observed in amygdaloid
ChAT activity between the treatment groups (Table 2). These data suggest that AP induced
histopathological changes within the amygdala are not associated with a loss of cholinergic
terminals projecting from the nucleus basalis. Alternatively, AP induced damage of
cholinergic terminals within the amygdala may lead to compensatory increase in ChA T
production within the cell bodies in the nucleus basalis. To investigate these possibilities, it
would be necessary to analyze ChAT activity within the nucleus basalis and/or to stain for
ChAT on brain sections.
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Overall, we have demonstrated reproducible histopathological effects of intraamygdaloid injections of

A~,

that may simulate the initial histopathological changes that

occur in AD. Alternatively, this approach models the in vivo histopathological effects of
deposition of A~ fibrils containing the same ~-sheet structure that is observed in senile
plaques in AD. Furthermore, in young inbred male Fischer-344 rats these changes are in
part transient, and are predominantly observed within the right amygdala and hippocampus.
Identification of the cause for the lateralized effect of

A~

25-35 may prove valuable by

giving insight into possible therapeutic strategies to slow the progression of AD. These
findings support the use of this rat model as a reliable tool to screen drugs that may alter
the initial pathological events associated with AD, that occur before the manifestations of
extensive behavioral impairments.

CHAPTER VI
GENERAL DISCUSSION

We have demonstrated that unilateral intra-amygdaloid injections of amyloid-P (AP)
25-35 in Fischer-344 rat induce the appearance of abnormal tau proteins both within the
ipsilateral amygdala, as well as at distant sites as recognized by the tau-2 and Alz-50
antibodies (317). These cytoskeletal changes were progressive (8 vs. 32 days) and
associated with reactive astrocytosis. Studies have reported local effects of AP injections
immediately surrounding the injection site in rat cerebral cortex and hippocampus
(91, 178, 180), but this is the first report on AP injections into the rat amygdala and their
distal effects.
We also examined the time course of the histopathological effects of bilateral
injections of AP 25-35 and sought to determine if these effects were associated with a
reduction in choline acetyltransferase (ChAT) activity and behavioral impairments (31 5,316).
AP 25-35 induced abnormal neuronal tau-2 and interleukin-1 p staining, and reactive
astrocytosis within the amygdala, as well as at distal sites such as the hippocampus. These
histological changes were associated with neuronal shrinkage within the amygdala.
Surprisingly, these changes were predominantly observed within the right hemisphere with
the left hemisphere significantly less affected. The effects of AP 25-35 peaked at 32 days
postoperatively. These histopathological effects were not associated with a reduction in
amygdaloid ChAT activity at 32 days postinjection. This is the first report that
demonstrates a laterality in the histopathological effects of AP, and it also shows that the
effects of single intra-amygdaloid injections are in part transient.
133
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In a separate experiment, behavioral effects of bilateral intra-amygdaloid injections of
AP 25-35 were analyzed 34-52 days postoperatively. In the open field test, the treatment
groups differed only in the numbers of rears emitted (p =0.016). There was no treatment
effect in the Morris water maze or in the acquisition and retention of a one-way conditioned
avoidance response. Thus, in young rats, AP induced histopathological changes are not
accompanied by major behavioral deficits, perhaps because the pathology is restricted to the
right hemisphere. The lack of extensive neuronal loss may also explain the lack of
behavioral deficits.
Together, these findings suggest a direct association between plaque and tangle
formation in Alzheimer's disease (AD), and support the use of this rat model to screen drugs
that may alter the initial pathological events associated with AD, that occur before the
manifestations of extensive behavioral impairments.
In an attempt to evaluate this model of the initial histopathological effects in AD, it is
necessary to compare it to reports of other animal models of this disease. It is clear that the
early animal models of AD (84, 134, 195), that attempted to mimic the loss of cholinergic
neurons in the basal forebrain in AD (12,57,351 ), are of limited use as a model of AD,
because they lacked the broad spectrum of pathological features of the disease. Neurons
producing norepinephrine, serotonin, dopamine, glutamate, y-aminobutyric acid,
somatostatin, neuropeptide Y, corticotrophin releasing factor, substance P, and other
neuromodulators are also affected in AD (54,56, 157, 177,288,327). Because of these
broad deficits in neurotransmitter systems, it is unlikely that AD can be treated by
transmitter replacement therapy alone. A more feasible approach is to develop compounds
that interfere with neuritic plaque and tangle formation, the major histopathological
hallmarks of the disease.
The discovery of AP as a major component of senile plaques and subsequent
findings of its in vitro neurotoxicity led to reports examining the in vivo effects of AP by
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microinjections of Aj3 into the brains of rats and monkeys. The toxic effects of Aj3 in vivo
have been inconsistent (42,91,99, 101, 102, 178, 180, 191,274,314-317,320,354). This
may be due to variations in: 1) conformational state (25,269,273), dose, and sequence of
Aj3; 2) method of administration; 3) pathological endpoints measured; 4) what brain region
and/or hemisphere is injected; 5) postoperative interval; and, 6) species and/or strain used.
It can be argued that because Aj3 1-42 is the most prevalent form of Aj3 in senile plaques, it
is appropriate to use that peptide for injections into brain instead of Aj3 25-35. However,
the main problem with using Aj3 1-42 is its insolubility in physiological solvents. Therefore,
there is a risk of potentially toxic solvents interfering with the properties and effects of Aj3
1-42. On the other hand, Aj3 25-35 is readily soluble in H 2 0 and acquires the same

13-

pleated sheet conformation as Aj3 1-42, which is the toxic conformation of Aj3. In addition
to injections of Aj3 alone, coadministration of heparan sulfate proteoglycans has been shown
to be important for consistent in vivo deposition and persistence of fibrillar Aj3 in the rat
hippocampus (321 ). Our studies represent the only comprehensive time course study that
has been reported on the histopathological effects of Aj3, and shows in contrast to other
studies ( 102,321) that Aj3 deposits can be observed consistently without coadministration
of other compounds and that these deposits are not degraded following intracerebral
administration in the rat. The reason for these discrepancies may be due to variations in
some of the experimental procedures mentioned above. For example, acetylcholinesterase
(AChE) has been shown to promote the formation of and/or stabilization of Aj3 fibrils (150),
and the basolateral amygdala, that is adjacent to the injection site in our studies, has one of
the highest levels of AChE of any brain structure (261 ).
Before our reports, a few in vivo studies had investigated the potential association
between plaque and tangle formation in AD by examining the effects of Aj3 injected into the
brain on tau IR (42,91,99, 178, 180,274). Some of these studies indicated that Aj3 can
induce the appearance of abnormal tau proteins in the vicinity of the injection site (rat
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cerebral cortex and hippocampus) (91, 178, 180). Other studies failed to show any effect
(42,99,274). For the most part, these in vivo studies were only qualitative or descriptive in
nature. Our reports are the first to attempt to quantify Af3 induced effects by counting
neuronal tau IR cells, to demonstrate distal cytoskeletal and astrogliotic changes, and to
investigate the time course of these histopathological effects of Af3. Overall, these findings
suggest an association between plaque and tangle formation in AD. It should be noted that
the rodent brain does not spontaneously form senile plaques or neurofibrillary tangles (50),
the main histopathological hallmarks of AD. Human and rodent Af3 differ in three amino
acids. As a consequence, the rat Af3 is much less fibrillogenic than the human Af3 (72) and
that may explain the lack of senile plaques in rodents. Rodent tau differs also from human
tau (3) and that may explain the lack of tangles in rodents. Tangles are formed in several
human neurodegenerative diseases besides AD (357) and may be a marker of specific form
of cell injury, such as slow neurodegeneration, in some but not all mammals.
The effects of Af3 on tau IR may be mediated through an increase in intracellular
calcium. Af3 has been shown to increase intracellular calcium (7,218), and calcium influx in
cultured rat hippocampal neurons caused by glutamate induces tau IR as recognized by the
antibodies Alz-50 and 5E2 (216). Protein kinases are generally activated by increases in
intracellular calcium and several of those have been shown to phosphorylate different sites
on tau proteins (238). Therefore, Af3 may increase the phosphorylation of tau proteins
through an activation of kinases mediated by an increase in intracellular calcium. The
activities of some phosphatases that may dephosphorylate tau proteins have been shown to
be decreased in AD (111,311 ). Therefore, Af3 25-35 may also be decreasing the
dephosphorylation of tau proteins through an inhibition of phosphatases.
There have been reports on the effects of intracranial Af3 injections on behavior.
These behavioral studies are difficult to compare because the experimental procedures
varied substantially. Because of the nature of behavioral experiments it is necessary to
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support alterations in behavior with neurochemical and/or histological findings. It is
interesting to note that although several of these studies demonstrate behavioral
impairments following A~ injections, few of these reports investigated the time course of
the histopathological and/or neurochemical changes caused by

A~,

to determine the most

appropriate postoperative interval to perform behavioral testing. It is possible that the
behavioral effects observed in some of these studies may be due to physical displacement of
brain tissue by high doses of

A~

rather than actual histopathological effects. The behavioral

effects obtained in our model were modest. In the three tests performed, there was a
significant difference between the treatment groups only in the number of rears in the open
field. These results were not surprising mostly because of the lateralized effects of

A~.

There is a consensus in the field of behavioral neuroscience that bilateral lesions are often
necessary to obtain behavioral deficits, because of compensation by the unlesioned side.
Although there have been several reports on transgenic approaches to model AD
(53,98, 137-139, 143, 145, 146, 186, 188,206,236,263,277,364) only two of these reports
appear to be promising (98, 145). These two mouse models contain age dependent compact
congophilic

A~

plaques similar to those observed in AD, and in one of these models these

changes are associated with behavioral impairments (145). The first of these models to be
described overexpresses

amyloid-~

precursor protein (APP) containing the APP71 7 mutation

that is associated with familial AD (98). These mice express 8-10 fold the normal level of
APP and have large numbers of amyloid plaques in the hippocampus, corpus callosum, and
cerebral cortex that first appear at 6-9 months of age. The majority of the plaques are
associated with reactive astrocytes and dystrophic neurites. The neocortices of these mice
exhibit diffuse synaptic and dendritic loss, and contain diffusely activated microglia. This
histopathology is region specific and age dependent as in AD, despite expression of the APP
transgene throughout the brain. These results suggest that region and/or cell type specific
vulnerability of the aging brain may dictate the pattern of plaque formation. A significant
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limitation of this model is the lack of neurofibrillary tangles, and their absence may reflect
species variations in neuronal response to injury. Also, in this model there have been no
reports of behavioral impairments associated with the histopathological changes.
The other promising transgenic mouse model (145) overexpresses a mutated form of
APP695 that has been found in a Swedish family with early-onset AD (242). These mice
express this human form at 5-6 fold the levels of endogenous mouse APP, that remains
unchanged between 2 and 14 months of age. These mice demonstrate normal learning and
memory in the Morris water maze and the Y maze at 3 months of age but are impaired by 9
to 10 months of age. A 5 fold increase in AP 1-40 and a 14 fold increase in AP 1-42 is
associated with these behavioral deficits. Numerous Congo red positive AP plaques are
present in mice with elevated AP levels. The distribution of the histopathological changes is
reportedly similar to that observed by Games et al. (98). The authors indirectly control for
impairments in motor performance but it is possible that the behavioral deficits may be
caused by visual impairments. This possibility, overlooked by the investigators, is based on
the impairment of the transgenic mice in swimming to a visible platform. Interestingly, other
transgenic approaches that are not associated with AD-like histopathology (146,364), or
that have only diffuse AP deposits that are not congophilic and lack neuritic involvement
(139), have been reported to lead to deficits in spatial memory in the Morris water maze
(236,364) and in the Y maze (146,236). As in the model by Hsiao et al. (145), both of the
models tested in the water maze showed significant impairments in initial learning
(236,364), suggesting that gene dosage effect or position effect of transgene integration
but not the AP deposition per se may lead to behavioral deficits. Furthermore, as in the
Hsiao model, the mice with the diffuse AP deposits ( 139) exhibited greater latency in
locating a visible platform in the water maze (236). This observation further suggests that
visual impairments may account for differences in performance. Interestingly, APP and AP
are present at low levels in normal lenses and AP has toxic effects on lens epithelial cells
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(94). APP is synthesized in retinal ganglion cells and transported into the optic nerve, in
which C-terminal amyloidogenic fragments accumulate (237), and there is an increased APP
IR in retinal ganglion cells of the elderly (198). Together, these findings emphasize the
importance of investigating possible vision impairments in APP transgenic animals.
In contrast to other APP transgenic models, the expression of the APP variant in
these two promising models (98, 145) substantially exceeds those of the endogenous mouse
APP gene. Because of the various proposed roles for APP, it is likely that a 5-1 O fold
increase in APP has several biological effects beside an increase in AP production and
subsequent plaque formation. There is no compelling evidence that sporadic AD is
associated with a global increase in APP expression (115). It is also possible that insertion
of multiple copies of any gene construct may impair cognitive function, because inheritance
of relatively small amounts of extra genomic DNA in human imbalanced translocation
karotypes results in mental retardation (364). The behavioral effects may also be due to
position effect of transgene integration that may interfere with the expression of other
genes.
Even though several in vitro studies have tested various hypotheses for the
mechanism by which AP exerts its toxic effect, these hypotheses have not been adequately
tested in in vivo situations. It is important to continue to explore the in vivo effects of AP
by direct injections into brain. Findings from these studies may help elucidate the sequence
of pathogenic events that ultimately lead to AD. In conjunction with transgenic models they
may also distinguish between the biological effects of AP and elevated levels of APP,
respectively.
Animal models can be evaluated in terms of construct validity, face validity and
predictive validity. We believe that our model has construct validity because we are
injecting a fragment of a peptide, that may play a prominent role in the etiology of AD, into
a brain region that is affected early in the disease. The most appropriate face validity of an
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animal model of AD would be the demonstration of senile plaques associated with reactive
astrocytes, neurofibrillary tangles, and neuronal shrinkage and cell loss in the same brain
regions as observed in AD. It is unlikely, however, that this effect can be obtained using a
single injection of

A~

into rat brain, but this approach may demonstrate the early

histopathological changes in AD. In my opinion, the present rat model has a relatively high
face validity because of the neuronal shrinkage and the induction of abnormal tau proteins
and reactive astrocytes in brain regions where the primary and early histopathological
changes in AD are observed. Currently, no definitive transgenic animal models are available
that resemble all aspects of AD, although plaque-like

A~

deposits have been observed

(98, 145), that in one model are associated with behavioral impairments (145). The
predictive validity of the present rat model, as well as current transgenic models, will
ultimately determine their usefulness in screening potential drugs for therapy.
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Figure 29. Pathological effects of Af3. A flow diagram showing a proposed scenario for the
pathological effects of Af3. The star symbol (*) represents phenomena analyzed in rats in
the present study. This figure represents an extremely simplified version of some of the
pathological processes that may be involved in the progression of AD.
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Future Directions
Because AD is an age related disorder it is necessary to investigate the effects of
intracerebral injections of

A~

in old animals. A detailed histological analysis of the whole rat

brain following intra-amygdaloid injections of

A~

will certainly be valuable. A comparison of

the regional pattern of histopathology with efferent and afferent projections of the amygdala
may provide insight into the mechanism of

A~

effects. However, a lack of pathology in a

brain region that has prominent projections to the amygdala will not necessarily disprove the
hypothesis that

A~

may be affecting nerve terminals. In AD there is a selective vulnerability

of brain regions and the pathological process occurs over decades. It is possible that
different regions and/or cell types of the brain have different kinetics and/or vulnerability for
A~

induced pathology. It would also be interesting to determine if multiple

A~

injections

administered through implanted cannula could lead to more severe behavioral impairments
than we observed following single injections. Behavioral testing using different behavioral
paradigms and/or postoperative interval may also be useful. The laterality observed
following bilateral intra-amygdaloid injections is a very surprising phenomenon. It is
important to determine if the laterality in the effects of

A~

is specific for the amygdala, or if

it can be observed following injections into other brain structures or following ventricular
infusions. Injections of

A~

into other strains and species are necessary to determine if the

histopathological effects and/or laterality are strain and/or species specific. Further
investigations into the cause for the lateralized effects of
addition, injections of

A~

1-40,

A~

A~

are also warranted. In

1-42, and other amyloidogenic peptides, co-injections of

other plaque components, and even injections of senile plaque cores may provide clues on
how prominent role the

~-sheet

structure of

A~

has in the process of AD histopathology.

Finally, it would be interesting to determine if compounds that interfere with
formation and/or enhance fibril degradation in vitro could affect

A~

A~

fibril

deposition and/or
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accelerate the in vivo degradation of the deposits. Anti-inflammatory compounds that easily
penetrate the blood-brain-barrier are also of potential interest to attenuate the
histopathological effects of intracerebral injections of A~.

Conclusion
In summary, the present model has histopathological features that are likely to occur
in the initial stages of AD but its predictive validity will ultimately determine its usefulness as
an animal model for AD.
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